<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1311234461
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SEQUIT 200 mg Film Coated Tablets
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        QUETIAPINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        68.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N05AH04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sequit&trade; contains an active substance called quetiapine. This belongs to a group of<br />medicines called anti-psychotics. Sequit&trade; can be used to treat several illnesses, such<br />as: &bull; Bipolar depression: where you feel sad. You may find that you feel depressed,<br />feel guilty, lack energy, lose your appetite or can&rsquo;t sleep.<br />&bull; Mania: where you may feel very excited, elated, agitated, enthusiastic or<br />hyperactive or have poor judgment including being aggressive or disruptive.<br />&bull; Schizophrenia: where you may hear or feel things that are not there, believe things<br />that are not true or feel unusually suspicious, anxious, confused, guilty, tense or<br />depressed.<br />Your doctor may continue to prescribe Sequit&trade; even when you are feeling better.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Sequit&trade;:<br />&bull; If you are allergic (hypersensitive) to quetiapine or any of the other ingredients of<br />Sequit&trade; (see Section 6: Further information).<br />&bull; If you are taking any of the following medicines:<br />- some medicines for HIV<br />- azole medicines (for fungal infections)<br />- erythromycin or clarithromycin (for infections)<br />- nefazodone (for depression).<br />Do not take Sequit&trade; if the above applies to you. If you are not sure, talk to your<br />doctor or pharmacist before taking Sequit&trade;.<br />Warnings and Precautions<br />Talk to your doctor or pharmacist before taking Sequit&trade; if:<br />&bull; You, or someone in your family, have or have had any heart problems, for example<br />heart rhythm problems, weakening of the heart muscle or inflammation of the heart<br />or if you are taking any medicines that may have an impact on the way your heart<br />beats.<br />&bull; You have low blood pressure.<br />&bull; You have had a stroke, especially if you are elderly.<br />&bull; You have problems with your liver.<br />&bull; You have ever had a fit (seizure).<br />&bull; You have diabetes or have a risk of getting diabetes. If you do, your doctor may<br />check your blood sugar levels while you are taking Sequit&trade;.<br />&bull; You know that you have had low levels of white blood cells in the past (which may<br />or may not have been caused by other medicines).<br />&bull; You are an elderly person with dementia (loss of brain function). If you are,<br />Sequit&trade; should not be taken because the group of medicines that Sequit&trade; belongs<br />to may increase the risk of stroke, or in some cases the risk of death, in elderly people<br />with dementia.<br />&bull; You or someone else in your family has a history of blood clots, as medicines like<br />these have been associated with formation of blood clots.<br />&bull; You have or have had a condition where you stop breathing for short periods during<br />your normal nightly sleep (called &ldquo;sleep apnoea&rdquo;) and are taking medicines that slow<br />down the normal activity of the brain (&ldquo;depressants&rdquo;).<br />&bull; You have or have had a condition where you can&rsquo;t completely empty your bladder<br />(urinary retention), have an enlarged prostate, a blockage in your intestines, or<br />increased pressure inside your eye. These conditions are sometimes caused by<br />medicines (called &ldquo;anti-cholinergics&rdquo;) that affect the way nerve cells function in<br />order to treat certain medical conditions.<br />Tell your doctor immediately if you experience any of the following after taking<br />Sequit&trade;:<br />&bull; A combination of fever, severe muscle stiffness, sweating or a lowered level of<br />consciousness (a disorder called &ldquo;neuroleptic malignant syndrome&rdquo;). Immediate<br />medical treatment may be needed.<br />&bull; Uncontrollable movements, mainly of your face or tongue.<br />&bull; Dizziness or a severe sense of feeling sleepy. This could increase the risk of<br />accidental injury (fall) in elderly patients.<br />&bull; Fits (seizures).<br />&bull; A long-lasting and painful erection (Priapism).<br />These conditions can be caused by this type of medicine. Tell your doctor as soon as<br />possible if you have:<br />&bull; A fever, flu-like symptoms, sore throat, or any other infection, as this could be a<br />result of a very low white blood cell count, which may require Sequit&trade; to be stopped<br />and/or treatment to be given.<br />&bull; Constipation along with persistent abdominal pain, or constipation which has not<br />responded to treatment, as this may lead to a more serious blockage of the bowel.<br />Thoughts of suicide and worsening of your depression<br />If you are depressed you may sometimes have thoughts of harming or killing<br />yourself. These may be increased when first starting treatment, since these medicines<br />all take time to work, usually about two weeks but sometimes longer. These thoughts<br />may also be increased if you suddenly stop taking your medication. You may be<br />more likely to think like this if you are a young adult. Information from clinical trials<br />has shown an increased risk of suicidal thoughts and/or suicidal behaviour in young<br />adults aged less than 25 years with depression.<br />If you have thoughts of harming or killing yourself at any time, contact your doctor<br />or go to a hospital straight away. You may find it helpful to tell a relative or close<br />friend that you are depressed, and ask them to read this leaflet. You might ask them<br />to tell you if they think your depression is getting worse, or if they are worried about<br />changes in your behaviour.<br />Weight gain<br />Weight gain has been seen in patients taking quetiapine. You and your doctor should<br />check your weight regularly.<br />Children and Adolescents<br />Sequit&trade; is not for use in children and adolescents below 18 years of age.<br />Other medicines and Sequit&trade;<br />Tell your doctor if you are taking or have recently taken any other medicines.<br />Do not take Sequit&trade; if you are taking any of the following medicines:<br />&bull; Some medicines for HIV.<br />&bull; Azole medicines (for fungal infections).<br />&bull; Erythromycin or clarithromycin (for infections).<br />&bull; Nefazodone (for depression).<br />Tell your doctor if you are taking any of the following medicines:<br />&bull; Epilepsy medicines (like phenytoin or carbamazepine).<br />&bull; High blood pressure medicines.<br />&bull; Barbiturates (for difficulty sleeping).<br />&bull; Thioridazine or Lithium (other anti-psychotic medicines).<br />&bull; Medicines that have an impact on the way your heart beats, for example, drugs that<br />can cause an imbalance in electrolytes (low levels of potassium or magnesium) such<br />as diuretics (water pills) or certain antibiotics (drugs to treat infections).<br />&bull; Medicines that can cause constipation.<br />Before you stop taking any of your medicines, please talk to your doctor first.<br />Sequit&trade; with food, drink and alcohol<br />&bull; Sequit&trade; can be taken with or without food.<br />&bull; Be careful how much alcohol you drink. This is because the combined effect of<br />Sequit&trade; and alcohol can make you sleepy.<br />&bull; Do not drink grapefruit juice while you are taking Sequit&trade;. It can affect the way<br />the medicine works.<br />Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or planning to have<br />a baby ask your doctor for advice before taking Sequit&trade;. You should not take<br />Sequit&trade; during pregnancy unless this has been discussed with your doctor. Sequit&trade;<br />should not be taken if you are breast-feeding.<br />The following symptoms which can represent withdrawal may occur in newborn<br />babies of mothers that have used Sequit&trade; in the last trimester (last three months of<br />their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation,<br />breathing problems, and difficulty in feeding. If your baby develops any of these<br />symptoms you may need to contact your doctor.<br />Driving and using machines<br />Your tablets may make you feel sleepy. Do not drive or use any tools or machines<br />until you know how the tablets affect you.<br />Sequit&trade; contains lactose<br />Sequit&trade; contains lactose which is a type of sugar. If you have been told by your<br />doctor that you have an intolerance to some sugars, talk to your doctor before taking<br />this medicine.<br />Effect on Urine Drug Screens<br />If you are having a urine drug screen, taking Sequit&trade; may cause positive results for<br />methadone or certain drugs for depression called tricyclic antidepressants (TCAs)<br />when some test methods are used, even though you may not be taking methadone or<br />TCAs. If this happens, a more specific test can be performed.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Sequit&trade; exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure. Your doctor will decide on your<br />starting dose. The maintenance dose (daily dose) will depend on your illness and<br />needs but will usually be between 150 mg and 800 mg.<br />&bull; You will take your tablets once a day, at bedtime or twice a day, depending on your<br />illness.<br />&bull; Swallow your tablets whole with a drink of water.<br />&bull; You can take your tablets with or without food.<br />&bull; Do not drink grapefruit juice while you are taking Sequit&trade;. It can affect the way<br />the medicine works.<br />&bull; Do not stop taking your tablets even if you feel better, unless your doctor tells you.<br />Liver problems<br />If you have liver problems your doctor may change your dose.<br />Elderly people<br />If you are elderly your doctor may change your dose.<br />Use in children and adolescents<br />Sequit&trade; should not be used by children and adolescents aged under 18 years.<br />If you take more Sequit&trade; than you should<br />If you take more Sequit&trade; than prescribed by your doctor, you may feel sleepy, feel<br />dizzy and experience abnormal heart beats. Contact your doctor or nearest hospital<br />straight away. Keep the Sequit&trade; tablets with you.<br />If you forget to take a dose of Sequit&trade;<br />If you forget to take a dose, take it as soon as you remember. If it is almost time to<br />take the next dose, wait until then. Do not take a double dose to make up for a<br />forgotten tablet.<br />If you stop taking Sequit&trade;<br />If you suddenly stop taking Sequit&trade;, you may be unable to sleep (insomnia), or you<br />may feel sick (nausea), or you may experience headache, diarrhoea, being sick<br />(vomiting), dizziness or irritability. Your doctor may suggest you reduce the dose<br />gradually before stopping treatment.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Sequit&trade; can cause side effects, although not everybody gets<br />them.<br />Very common side effects (may affect more than 1 in 10 people):<br />&bull; Dizziness (may lead to falls), headache, dry mouth.<br />&bull; Feeling sleepy (this may go away with time, as you keep taking Sequit&trade;)<br />(may lead to falls).<br />&bull; Discontinuation symptoms (symptoms which occur when you stop taking Sequit&trade;)<br />include not being able to sleep (insomnia), feeling sick (nausea), headache, diarrhoea,<br />being sick (vomiting), dizziness and irritability. Gradual withdrawal over a period of<br />at least 1 to 2 weeks is advisable.<br />&bull; Putting on weight.<br />&bull; Abnormal muscle movements. These include difficulty starting muscle movements,<br />shaking, feeling restless or muscle stiffness without pain.<br />&bull; Changes in the amount of certain fats (triglycerides and total cholesterol).<br />Common side effects (may affect up to 1 in 10 people):<br />&bull; Rapid heartbeat.<br />&bull; Feeling like your heart is pounding, racing or has skipped beats.<br />&bull; Constipation, upset stomach (indigestion).<br />&bull; Feeling weak.<br />&bull; Swelling of arms or legs.<br />&bull; Low blood pressure when standing up. This may make you feel dizzy or faint (may<br />lead to falls).<br />&bull; Increased levels of sugar in the blood.</p><p>&bull; Blurred vision.<br />&bull; Abnormal dreams and nightmares.<br />&bull; Feeling more hungry.<br />&bull; Feeling irritated.<br />&bull; Disturbance in speech and language.<br />&bull; Thoughts of suicide and worsening of your depression.<br />&bull; Shortness of breath.<br />&bull; Vomiting (mainly in the elderly).<br />&bull; Fever.<br />&bull; Changes in the amount of thyroid hormones in your blood.<br />&bull; Decreases in the number of certain types of blood cells.<br />&bull; Increases in the amount of liver enzymes measured in the blood.<br />&bull; Increases in the amount of the hormone prolactin in the blood. Increases in the<br />hormone prolactin could in rare cases lead to the following:<br />Men and women to have swelling breasts and unexpectedly produce breast milk.<br />Women to have no monthly periods or irregular periods.<br />Uncommon side effects (may affect up to 1 in 100 people):<br />&bull; Fits or seizures.<br />&bull; Allergic reactions that may include raised lumps (weals), swelling of the skin and<br />swelling around the mouth.<br />&bull; Unpleasant sensations in the legs (also called restless legs syndrome).<br />&bull; Difficulty swallowing.<br />&bull; Uncontrollable movements, mainly of your face and tongue.<br />&bull; Sexual dysfunction.<br />&bull; Diabetes.<br />&bull; Change in electrical activity of the heart seen on ECG (QT prolongation).<br />&bull; A slower than normal heart rate which may occur when starting treatment and<br />which may be associated with low blood pressure and fainting.<br />&bull; Difficulty in passing urine.<br />&bull; Fainting (may lead to falls).<br />&bull; Stuffy nose.<br />&bull; Decrease in the amount of red blood cells.<br />&bull; Decrease in the amount of sodium in the blood.<br />&bull; Worsening of pre-existing diabetes.<br />Rare side effects (may affect up to 1 in 1,000 people):<br />&bull; A combination of high temperature (fever), sweating, stiff muscles, feeling very<br />drowsy or faint (a disorder called &ldquo;neuroleptic malignant syndrome&rdquo;).<br />&bull; Yellowing of the skin and eyes (jaundice).<br />&bull; Inflammation of the liver (hepatitis).<br />&bull; A long-lasting and painful erection (priapism).<br />&bull; Swelling of breasts and unexpected production of breast milk (galactorrhoea).<br />&bull; Menstrual disorder.<br />&bull; Blood clots in the veins especially in the legs (symptoms include swelling, pain and<br />redness in the leg), which may travel through blood vessels to the lungs causing chest<br />pain and difficulty in breathing. If you notice any of these symptoms seek medical<br />advice immediately.<br />&bull; Walking, talking, eating or other activities while you are asleep.<br />&bull; Body temperature decreased (hypothermia).<br />&bull; Inflammation of the pancreas.<br />&bull; A condition (called &ldquo;metabolic syndrome&rdquo;) where you have a combination of 3 or<br />more of the following: an increase in fat around your abdomen, a decrease in &ldquo;good<br />cholesterol&rdquo; (HDL-C), an increase in a type of fat in your blood called triglycerides,<br />high blood pressure and an increase in your blood sugar.<br />&bull; Combination of fever, flu-like symptoms, sore throat, or any other infection with<br />very low white blood cell count, a condition called agranulocytosis.<br />&bull; Bowel obstruction.<br />&bull; Increased blood creatine phosphokinase (a substance from the muscles).<br />Very rare side effects (may affect up to 1 in 10,000 people):<br />&bull; Severe rash, blisters, or red patches on the skin.<br />&bull; A severe allergic reaction (called anaphylaxis) which may cause difficulty in<br />breathing or shock.<br />&bull; Rapid swelling of the skin, usually around the eyes, lips and throat (angioedema).<br />&bull; A serious blistering condition of the skin, mouth, eyes and genitals<br />(Stevens-Johnson syndrome).<br />&bull; Inappropriate secretion of a hormone that controls urine volume.<br />&bull; Breakdown of muscle fibers and pain in muscles (rhabdomyolysis).<br />Not known (frequency cannot be estimated from the available data):<br />&bull; Skin rash with irregular red spots (erythema multiforme).<br />&bull; Serious, sudden allergic reaction with symptoms such as fever and blisters on the<br />skin and peeling of the skin (toxic epidermal necrolysis).<br />&bull; Symptoms of withdrawal may occur in newborn babies of mothers that have used<br />Sequit&trade; during their pregnancy.<br />The class of medicines to which Sequit&trade; belongs can cause heart rhythm problems,<br />which can be serious and in severe cases may be fatal.<br />Some side effects are only seen when a blood test is taken. These include changes in<br />the amount of certain fats (triglycerides and total cholesterol) or sugar in the blood,<br />changes in the amount of thyroid hormones in your blood, increased liver enzymes,<br />decreases in the number of certain types of blood cells, decrease in the amount of red<br />blood cells, increased blood creatine phosphokinase (a substance in the muscles),<br />decrease in the amount of sodium in the blood and increases in the amount of the<br />hormone prolactin in the blood. Increases in the hormone prolactin could in rare cases<br />lead to the following:<br />&bull; Men and women to have swelling of the breasts and unexpectedly produce breast<br />milk.<br />&bull; Women to have no monthly period or irregular periods. Your doctor may ask you to<br />have blood tests from time to time.<br />Side effects in children and adolescents<br />The same side effects that may occur in adults may also occur in children and<br />adolescents.<br />The following side effects have been seen more often in children and adolescents or<br />have not been seen in adults:<br />Very Common side effects (may affect more than 1 in 10 people):<br />&bull; Increase in the amount of a hormone called prolactin, in the blood. Increases in the<br />hormone prolactin could in rare cases lead to the following:<br />- boys and girls to have swelling of breasts and unexpectedly produce breast milk<br />- girls to have no monthly period or irregular periods.<br />&bull; Increased appetite.<br />&bull; Vomiting.<br />&bull; Abnormal muscle movements. These include difficulty starting muscle movements,<br />shaking, feeling restless or muscle stiffness without pain.<br />&bull; Increase in blood pressure.<br />Common side effects (may affect up to 1 in 10 people):<br />&bull; Feeling weak, fainting (may lead to falls).<br />&bull; Stuffy nose.<br />&bull; Feeling irritated.<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any<br />possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of reach and sight of children.<br />&bull; Do not use Sequit&trade; after the expiry date which is stated on the container after EXP.<br />&bull; Do not store above 30&deg;C.<br />&bull; Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will<br />help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Sequit&trade; contains:<br />Sequit&trade; 25 mg:<br />Each film coated tablet contains 25 mg of Quetiapine (as Quetiapine Fumarate).<br />Sequit&trade; 100 mg:<br />Each film coated tablet contains 100 mg of Quetiapine (as Quetiapine Fumarate).<br />Sequit&trade; 200 mg:<br />Each film coated tablet contains 200 mg of Quetiapine (as Quetiapine Fumarate).<br />Sequit&trade; 300 mg:<br />Each film coated tablet contains 300 mg of Quetiapine (as Quetiapine Fumarate).<br />The other ingredients are:<br />Core:<br />Lactose Monohydrate, Dibasic calcium Phosphate Dihydrate, Microcrystalline<br />cellulose, Povidone, Sodium starch Glycollate, Colloidal Silicone Dioxide,<br />Magnesium stearate.<br />Coating:<br />Opadry White 03B28796 (which consists of Hypromellose, Titanium dioxide,<br />Polyethylene Glycol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Sequit™ 25 mg: White coloured, round, biconvex, film coated tablets, debossed
with '05' one side and "JP" on other side.
Sequit™ 100 mg: White coloured, round, biconvex, film coated tablets, debossed
with '128' one side and "JP" on other side.
Sequit™ 200 mg: White coloured, Capsule shaped, biconvex, film coated tablets,
debossed with '129' one side and "JP" on other side.
Sequit™ 300 mg: White coloured, Capsule shaped, biconvex, film coated tablets,
debossed with '130' one side and "JP" on other side.
Sequit™ film coated tablets are available in 25 mg, 100 mg, 200 and 300 mg in boxes
of 30 tablets each.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 08/2016; Version number 01.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>1. ما هو عقار سيكويت&trade; و ماهي دواعي إستعماله.</p><p>&nbsp;</p><p>يحتوي عقار سيكويت&trade; على مادة فعالة تُسمى كوتايبين. ينتمي هذا العقار إلى مجموعة من الأدوية تُسمى مضادات الذهان. يمكن استخدام عقار سيكويت&trade; لعلاج العديد من الأمراض، مثل:</p><p>&bull; الاكتئاب ثنائي القطب: وفيه يشعر المصاب بالحزن. قد تجد أنك تشعر بالاكتئاب أو بالذنب أو بنقص الطاقة أو بفقدان الشهية أو عدم القدرة على النوم.</p><p>&bull; الهوس: وفيه يشعر المصاب بإثارة شديدة أو ابتهاج أو هياج أو حماس أو فرط نشاط أو يصاب بضعف القدرة على الحكم على الأمور، ويشمل ذلك العدوانية أو الاضطراب.</p><p>&bull; الفُصَام: وفي هذه الحالة يتوهم المصاب سماع أصوات أو الشعور بأشياء لا وجود لها، ويصدق أمورًا غير حقيقية أو يشعر بالارتياب على غير العادة أو بالقلق أو الارتباك/ الالتباس أو الذنب أو التَّوتر أو الاكتئاب.</p><p>قد يواصل طبيبك وصف عقار سيكويت&trade; لك حتى إذا شعرت بتحسن</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>2. ما الذي تحتاج إلى معرفته قبل تناول عقار سيكويت&trade;.</p><p>&nbsp;</p><p>لا تتناول عقار سيكويت&trade; في الحالات الآتية:</p><p>&bull; إذا كنت تعاني من حساسية (فرط الحساسية) تجاه كوتايبين أو أي من المكونات الأخرى بعقار سيكويت&trade; (انظر قسم 6: مزيد من المعلومات).</p><p>&bull; أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p>- بعض الأدوية لعلاج فيروس نقص المناعة البشرية</p><p>- الأدوية التي تنتمي لمجموعة أزول (لعلاج العدوى الفطرية).</p><p>- إريثروميسين أو كلاريثروميسين (لعلاج العدوى).</p><p>- نيفازودون (لعلاج الاكتئاب).</p><p>لا تتناول عقار سيكويت&trade; إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدًا من كيفية التَّناول تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار سيكويت&trade;.</p><p>&nbsp;</p><p>تحذيرات واحتياطات</p><p>تحدَّث إلى طبيبك أو الصيدلي الخاص بك قبل تناوُل عقار سيكويت&trade;:</p><p>&bull; إذا كنت تعاني أو كان أحد أفراد أسرتك يعاني أو عانى سابقًا من مشاكل بالقلب، على سبيل المثال مشاكل في النَّظم القلبي، ضعف عضلة القلب أو التهاب القلب أو إذا كنت تتناول أدوية قد تُؤثر على نبض القلب.</p><p>&bull; إذا كنت تعاني من انخفاض ضغط الدَّم (هبوط).</p><p>&bull; كنت أُصبت بسكتة دماغية؛ خاصةً إذا كنت من كبار السن.</p><p>&bull; إذا كنت تعاني من مشاكل بالكبد.</p><p>&bull; إذا كنت قد عانيت من قبل من نوبة (نوبة تشنجية).</p><p>&bull; إذا كنت مصابًا بمرض السُّكَّرِي أو معرضًا للإصابة به. في هذه الحالة، قد يتحقق طبيبك من مستوى السكر في الدَّم لديك خلال فترة تناوُلك لعقار سيكويت&trade;.</p><p>&bull; إذا كنت تعلم أنك قد أصبت سابقًا بانخفاض خلايا الدَّم البيضاء (نتج أو لم ينتج عن تلقي أدوية أخرى).</p><p>&bull; إذا كنت من كبار السن المصابين بالخرف (ضعف وظائف المخ). إذا كنت كذلك، يجب عليك الامتناع عن تناوُل عقار سيكويت&trade; لأن المجموعة الدَّوائية التي ينتمي إليها عقار سيكويت&trade; قد ترفع خطر الإصابة بالسكتة الدماغية، أو خطر الوفاة في بعض الحالات في كبار السن المصابين بالخرف.</p><p>&bull; إذا كنت أنت أو شخص آخر في عائلتك لديه تاريخ مرضي سابق من الإصابة بالجلطات الدَّموية؛ حيث إنه قد تم الربط بين تلك الأدوية وتكوُّن جلطات الدَّم.</p><p>&bull; إذا كان لديك الان أو سابقاً حالة من التوقف عن التنفس لفترات قصيرة أثناء نومك العادي ليلا (وتسمى &quot;توقف التنفس أثناء النوم&quot;) وتأخذ أدوية تبطئ النشاط الطبيعي للمخ (&quot;مضادات الاكتئاب&quot;).</p><p>&bull; إذا كان لديك الان أو سابقاً حالة حيث لا يمكنك تفريغ المثانة تماما (احتباس البول)، لديك تضخم في البروستات، انسداد في الأمعاء أو زيادة الضغط داخل عينك. وتحدث هذه الحالات أحيانا بسبب بعض الأدوية (وتسمى &quot;مضادات الكولين&quot;) التي تؤثر على طريقة عمل الخلايا العصبية من أجل علاج بعض الحالات المرضية.</p><p>&nbsp;</p><p>أخبر طبيبك فورًا إذا تعرضت لأي من الآثار الجانبية التَّالية بعد تناوُل عقار سيكويت&trade;:</p><p>&bull; مزيج من الحمى وتصلب العضلات الشَّديد، أو التَّعرق أو انخفاض مستوى الوعي (اضطراب يدعى &quot;المتلازمة الخبيثة للدَّواء المضاد للذهان&quot;). قد تحتاج لعلاج طبي فورًا.</p><p>&bull; حركات لا يمكن السيطرة عليها في الوجه أو اللسان بصفة أساسية.</p><p>&bull; دوخة أو إحساس شديد بالنُّعاس. قد يرفع هذا خطر الإصابة بالحوادث (السقوط) في المرضى من كبار السن.</p><p>&bull; نوبات (نوبات تشنجية).</p><p>&bull; انتصاب طويل الأمد ومؤلم (قساح).</p><p>قد يُسبب هذه الحالات هذا النوع من الدَّواء. اتصل بطبيبك في أسرع وقت ممكن في الحالات الآتية:</p><p>&bull; حمى، أعراض شبيهة بالإنفلونزا، التهاب الحلق أو أي عدوى أخرى؛ إذ قد ينتج هذا عن انخفاض شديد في تعداد خلايا الدَّم البيضاء قد يتطلب وقف العلاج بعقار سيكويت&trade; و/أو إعطاء علاج.</p><p>&bull; إمساك مصحوب بألم مستمر في البطن، أو إمساك لا يستجيب للعلاج؛ إذ قد يُؤدي هذا إلى انسداد أكثر خطورة للأمعاء.</p><p>&nbsp;</p><p>الأفكار الانتحارية وتفاقم الاكتئاب لديك</p><p>إذا كنت مكتئبًا فيُمكِن في بعض الأحيان أن يكون لديك أفكار لإيذاء نفسك أو قتلها. قد تزداد هذه الأفكار عند بدء تناوُل العلاج لأول مرة، نظرًا إلى أن جميع هذه الأدوية تستغرق وقتًا حتى تعمل، عادةً يستغرق الأمر أسبوعين تقريبًا ولكن في بعض الأحيان يستغرق فترة أطول. قد تتزايد أيضًا هذه الأفكار لديك إذا قررت فجأة وقف تلقي دوائك. قد تكون أكثر عرضة للأفكار الانتحارية إذا كنت من الشباب البالغين. أظهرت المعلومات المستقاة من التجارب السريرية ارتفاع نسبة الأفكار الانتحارية و/ أو خطورة السلوك الانتحاري لدى صغار البالغين الذين تقل أعمارهم عن 25 سنة ممن يعانون من اكتئاب.</p><p>إذا كان لديك أفكار حول إيذاء نفسك أو قتلها في أي وقت، فاتصل بطبيبك أو اذهب إلى المستشفى على الفور. قد تجد أنه من المفيد إخبار أحد الأقارب أو الأصدقاء المقربين أنك مريض بالاكتئاب، ومطالبتهم بقراءة هذه النَّشرة. قد تطلب منهم أن يخبروك بما إذا كانوا يعتقدون أن مرض الاكتئاب يتفاقم لديك، أو ما إذا كانوا قلقين بشأن التَّغيرات الطارئة على سلوكك.</p><p>&nbsp;</p><p>زيادة الوزن</p><p>لُوحظت زيادة في الوزن في المرضى الذين يتلقون عقار كوتايبين. يجب أن تتحقق أنت أو طبيبك من وزنك بصفة مستمرة.</p><p>&nbsp;</p><p>الأطفال والمراهقون</p><p>عقار سيكويت&trade; غير مخصص للاستخدام في الأطفال والمراهقين أقل من 18 سنة.</p><p>&nbsp;</p><p>تناوُل عقار سيكويت&trade; مع أدوية أخرى</p><p>يُرجى إبلاغ طبيبك إذا كنت تتناول أو تناولت مؤخرًا أيَّة أدوية أخرى. لا يجب أبدًا أن تتناول عقار سيكويت&trade; إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p>&bull; بعض الأدوية لعلاج فيروس نقص المناعة البشرية.</p><p>&bull; الأدوية التي تنتمي لمجموعة أزول (لعلاج العدوى الفطرية).</p><p>&bull; إريثروميسين أو كلاريثرومايسين (لعلاج العدوى).</p><p>&bull; نيفازودون (لعلاج الاكتئاب).</p><p>أخبر طبيبك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p>&bull; أدوية الصَّرع (مثل: فينتوين أو كَرْبامازِيبين).</p><p>&bull; أدوية لعلاج ارتفاع ضغط الدَّم.</p><p>&bull; الباربيتيورات (لعلاج صعوبة النَّوم).</p><p>&bull; ثيوريدازين أو الليثيوم (أدوية أخرى مضادة للذهان).</p><p>&bull; أدوية تُؤثر على نبض القلب، على سبيل المثال: أدوية قد تُسبب عدم توازن الإليكتروليتات (مستويات منخفضة من البوتاسيوم أو الماغنسيوم) مثل: مدرات البول (أقراص الماء) أو مضادات حيوية معينة (أدوية لعلاج العدوى).</p><p>&bull; أدوية قد تُسبب الإمساك.</p><p>قبل أن تتوقف عن تناوُل أي أدوية خاصة بك، يُرجى التَّحدث مع طبيبك أولًا.</p><p>&nbsp;</p><p>تناول عقار سيكويت&trade; مع الأطعمة والمشروبات والكحوليات</p><p>يمكن تناول عقار سيكويت&trade; مع الطعام أو بدونه.</p><p>&bull; انتبه لكمية الكحوليات التي تتناولها. و ذلك لأن التَّأثير المركب لعقار سيكويت&trade; والكحوليات قد يشعرك بالنعاس.</p><p>&bull; لا تتناول عصير الجريب فروت أثناء تناوُلك لعقار سيكويت&trade;. فقد يُؤثر على آلية عمل الأدوية الأخرى.</p><p>&nbsp;</p><p>الحمل والرَّضاعة الطبيعية</p><p>إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ حامل أو تخططين لذلك، فاستشيري طبيبكِ قبل تناوُل عقار سيكويت&trade;. يجب ألا تتناولي عقار سيكويت&trade; أثناء الحمل إلا إذا كنتِ قد ناقشتِ ذلك مع طبيبكِ. يجب عليكِ الامتناع عن تناوُل عقار سيكويت&trade; إذا كنتِ مرضعًا.</p><p>قد تحدث الأعراض التَّالية في الأطفال حديثي الولادة، للأمهات اللاتي كن قد استخدمن عقار سيكويت&trade; في الثلث الأخير من الحمل (الثلاثة أشهر الأخيرة من الحمل): ارتعاش، وتصلب العضلات و/ أو ضعف العضلات ونعاس وهِياج و مشاكل بالتَّنفس وصعوبة في التَّغذية. إذا تطورت لدى طفلك أيٌّ من هذه الأعراض فقد تحتاجين إلى الاتصال بطبيبك.</p><p>&nbsp;</p><p>القيادة واستخدام الآلات</p><p>قد يُشعرك تناوُل أقراص الدَّواء بالنُّعاس. تجنب القيادة أو استخدام أي أدوات أو آلات حتى تعرف كيف تُؤثر الأقراص عليك.</p><p>&nbsp;</p><p>يحتوي عقار سيكويت&trade; على اللاكتوز</p><p>يحتوي عقار سيكويت&trade; على اللاكتوز وهو نوع من السكر. إذا كان طبيبك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، أخبر طبيبك قبل تناول هذا الدَّواء.</p><p>&nbsp;</p><p>التَّأثيرات على فحوصات الأدوية بالبول</p><p>إذا خضعت لفحص للكشف عن الأدوية بالبول، قد يُؤدي تناوُلك لعقار سيكويت&trade; إلى نتيجة إيجابية لوجود ميثادون أو بعض الأدوية الأخرى لعلاج الاكتئاب تدعى مضادات الاكتئاب ثلاثية الحلقات في البول لديك و ذلك عند استخدام بعض طرق الفحص، حتى إذا لم تكن تتناول ميثادون أو مضادات الاكتئاب ثلاثية الحلقات. في حالة حدوث ذلك ، يمكن إجراء اختبار أكثر دقة .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>3. كيفية تناول عقار سيكويت&trade;</p><p>&nbsp;</p><p>تناول عقار سيكويت&trade; دائماً كما أخبرك طبيبك بالضبط. يجب مراجعة الطبيب أو الصيدلي إذا لم تكن متأكداً من كيفية التَّناوُل. سيحدد طبيبك جرعة البدء الخاصة بك. تعتمد جرعة المداومة (الجرعة اليومية) على مرضك واحتياجك لكنها ستتراوح عادة ما بين 150 ملجم و800 ملجم .</p><p>&bull; ستتناول أقراص العقار مرة يوميًّا عند موعد النَّوم أو مرتين يوميًّا حسب مرضك.</p><p>ابلع القرص كاملاً مع شرب الماء.</p><p>&bull; يمكنك تناول الأقراص مع الطعام أو بدونه.</p><p>&bull; لا تتناول عصير الجريب فروت أثناء تناوُلك لعقار سيكويت&trade;. فقد يُؤثر على آلية عمل الدَّواء.</p><p>&bull; لا تتوقف عن تناول الأقراص إذا شعرت بتحسن، ما لم يخبرك الطبيب بذلك.</p><p>&nbsp;</p><p>مشاكل الكبد</p><p>إذا كان لديك مشاكل بالكبد، فقد يغير طبيبك جرعتك.</p><p>&nbsp;</p><p>المرضى من كبار السن</p><p>إذا كنت من كبار السن، فقد يغير طبيبك جرعتك.</p><p>&nbsp;</p><p>الاستعمال في الأطفال والمراهقين</p><p>يجب عدم استخدام عقار سيكويت&trade; من قبل الأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا.</p><p>&nbsp;</p><p>إذا تناولت كمية من عقار سيكويت&trade; أكثر مما يجب</p><p>إذا تناولت كمية أكثر من الكمية التي وصفها لك طبيبك من عقار سيكويت&trade;، فقد تشعر بالنعاس والدوخة وتعاني من اضطراب ضربات القلب. اتصل بطبيبك أو أقرب مستشفى للحصول على استشارة. احتفظ بأقراص عقار سيكويت&trade; معك.</p><p>&nbsp;</p><p>إذا نسيت تناول جرعة من عقار سيكويت&trade;</p><p>إذا نسيت تناوُل إحدى الجرعات، فتناولها بمجرد تذكرك لها. إذا اقترب موعد الجرعة التَّالية، انتظر حتى قدوم موعدها. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية .</p><p>&nbsp;</p><p>إذا توقفت عن تناول عقار سيكويت&trade;</p><p>إذا توقفت فجأة عن تناول عقار سيكويت&trade;، قد تجد صعوبة في النوم (أرق)، أو قد تشعر بالإعياء (غثيان)، أو قد تعاني صداعاً أو إسهالاً أو (التقيؤ) أو دوخة أو هياجاً. قد يقترح طبيبك عليك خفض الجرعة تدريجيًّا قبل وقف العلاج.</p><p>إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر الطبيب أو الصيدلي الخاص بك</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>4. الآثار الجانبية المُحتملة</p><p>&nbsp;</p><p>مثل كافة الأدوية، قد يُسبب عقار سيكويت&trade; آثارًا جانبية، على الرغم من أنها لا تحدث للجميع.</p><p>الآثار الجانبية الشائعة جدًّا (قد تُؤثر على أكثر من شخص 1 من بين كل 10&nbsp;أشخاص):</p><p>&bull; دوخة (قد تؤدي إلى إغماء)، وصداع، وجفاف بالفم.</p><p>&bull; شعور بالنُّعاس (قد يزول مع الوقت مع استمرارك في تناول عقار سيكويت&trade;) (قد يُؤدي إلى السقوط).</p><p>&bull; أعراض وقف الدَّواء (أعراض تحدث عند وقف تناوُل عقار &quot;سيكويت&trade; )، تشمل عدم القدرة على النوم (أرق)، (شعورًا بالإعياء (غثيان)، صداع، إسهال، إعياء (القيْ)، دوخةوهياج. وعليه يوصى بالامتناع التدريجي خلال فترة لا تقل عن أسبوع إلى أسبوعين.</p><p>&bull; زيادة الوزن.</p><p>&bull; حركة عضلات غير طبيعية. تشمل صعوبة في بدء حركة العضلات، والارتجاف، والشعور بالتململ أو تصلب بالعضلات غير مصحوب بألم.</p><p>&bull; زيادة في كمية بعض الدهون (الدهون الثلاثية وإجمالي الكوليسترول).</p><p>&nbsp;</p><p>الآثار الجانبية الشَّائعة (قد تُؤثر في ما يصل إلى شخص 1 من بين كل 10&nbsp;أشخاص):</p><p>&bull; سرعة ضربات القلب.</p><p>&bull; شعور بخفقان في القلب، تسرع ضربات القلب أو تفويت بعض ضربات القلب.</p><p>&bull; إمساك، تهيُّج المعدة (عسر هضم).</p><p>&bull; شعور بالضعف.</p><p>&bull; تورم الذراعين أو الساقين.</p><p>&bull; انخفاض ضغط الدَّم عند الوقوف قد يشعرك هذا بالدوخة أو بالإغماء</p><p>(قد يقع المريض).</p><p>&bull; تزايد مستويات السكر في الدَّم.</p><p>&bull; عدم وضوح الرؤية.</p><p>&bull; كوابيس وأحلام غير عادية.</p><p>&bull; تزايد الشعور بالجوع.</p><p>&bull; شعور بالهياج.</p><p>&bull; اضطراب في النطق والكلام.</p><p>&bull; الأفكار الانتحارية وتفاقم الاكتئاب لديك</p><p>&bull; ضيق في التَّنفس.</p><p>&bull; قيء (في كبار السن بصفة أساسية).</p><p>&bull;حمى.</p><p>&bull; تغيرات في كمية هرمونات الغدة الدَّرقية في الدَّم لديك.</p><p>&bull; انخفاض في عدد أنواع معينة من خلايا الدَّم.</p><p>&bull; ارتفاع بإنزيمات الكبد في الدَّم.</p><p>&bull; ارتفاع هرمون البرولاكتين بالدَّم. تزايد في مستوى هرمون البرولاكين قد يُؤدي في حالات نادرة إلى التَّالي:</p><p>تورم الثدي لدى الرجال والسيدات وإفراز لبن من الثدي بشكل غير متوقع. انقطاع الدَّورة الشهرية لدى السيدات أو عدم انتظام الدَّورة الشهرية.</p><p>&nbsp;</p><p>الآثار الجانبية غير الشائعة (قد تُؤثر في ما يصل إلى 1 من كل 100 شخص)</p><p>&bull; نوبات أو التشنجات.</p><p>&bull; تفاعلات حساسية قد تشمل: كتلا بارزة (الانتبار)، تورم الجلد وتورم حول الفم.</p><p>&bull; شعور بالضيق في الساقين (يدعى أيضًا متلازمة تململ الساقين).</p><p>&bull; صعوبة في البلع.</p><p>&bull; حركات لا يمكن السيطرة عليها،و تكون بصفة أساسية&nbsp; في الوجه واللسان .</p><p>&bull; اختلال الوظيفة الجنسية.</p><p>&bull; مرض السُّكَّرِي.</p><p>&bull; تغير في النشاط الكهربي للقلب ملاحظ على رسم القلب الكهربائي (إطالة فترة QT).</p><p>&bull; بطء معدل ضربات القلب عن المعدل الطبيعي قد يحدث عند بدء العلاج، وقد يكون مصحوباً بانخفاض بضغط الدَّم وإغماء.</p><p>&bull; صعوبة في التَّبول.</p><p>&bull; إغماء (قد يُؤدي إلى السقوط).</p><p>&bull; انسداد الأنف.</p><p>&bull; انخفاض في عدد خلايا الدَّم الحمراء.</p><p>&bull; انخفاض مستوى الصوديوم بالدَّم.</p><p>&bull; تفاقم مرض السُّكَّرِي القائم.</p><p>&nbsp;</p><p>الآثار الجانبية النَّادرة (قد تؤثر في ما يصل إلى 1 من كل 1,000&nbsp;شخص):</p><p>&bull; مزيج من ارتفاع درجة الحرارة (الحمى)، تعرق، تصلب العضلات، شعور شديد بالنعاس أو الضعف (اضطراب يدعى: &quot;المُتَلَازِمَةُ الخَبيثَةُ للدَّواءِ المُضادِّ للذُّهان&quot;).</p><p>&bull; اصفرار الجلد والعينين (يرقان).</p><p>&bull; التهاب الكبد.</p><p>&bull; انتصاب مؤلم طويل الأمد (القساح).</p><p>&bull; تورم الثدي وإفراز لبن من الثدي بشكل غير متوقع (ثر اللبن).</p><p>&bull; اضطرابات الدورة الشهرية.</p><p>&bull; تجلط الدَّم بالأوردة خاصةً بالساقين (تتضمن الأعراض: التورم، الألم، والاحمرار في الساق), والتي قد تنتقل عبر الأوعية الدَّموية إلى الرئتين وتتسبب في ألم في الصدر وصعوبة في التَّنفس. إذا لاحظت أيًّا من هذه الأعراض، فأسعي في طلب المشورة الطبية على الفور.</p><p>&bull; المشي أو الكلام أو تناول الطعام أو مزاولة أنشطة أخرى أثناء النوم.</p><p>&bull; انخفاض حرارة الجسم.</p><p>&bull; التهاب البنكرياس.</p><p>&bull; حالة تدعى: (&quot;متلازمة الاستقلاب&quot;) يحدث فيها بالتَّزامن ثلاث حالات أو أكثر من الحالات التَّالية: ارتفاع في مستوى الدهون حول البطن، انخفاض مستوى &quot;الكوليسترول المفيد&quot; (كوليسترول البروتين الدهني عالي الكثافة) وارتفاع في مستوى نوع من الدهون في الدَّم يدعى الدهون الثلاثية، وارتفاع ضغط الدَّم وارتفاع مستوى السكر بالدَّم.</p><p>&bull; مزيج من الحمى والأعراض الشبيهة بأعراض الإنفلونزا، والتهاب الحلق، أو أي عدوى أخرى مصحوبة بانخفاض شديد في تعداد خلايا الدَّم البيضاء يدعى: &quot;ندرة خلايا المحببات&quot;.</p><p>&bull; انسداد الأمعاء.</p><p>&bull; تزايد مستوى فسْفُوكيناز الكرياتين بالدَّم (مادة تفرز من العضلات).</p><p>&nbsp;</p><p>الآثار الجانبية النَّادرة جدًّا (قد تؤثر في ما يصل إلى شخص 1 من كل 10,000&nbsp;شخص):</p><p>&bull; طفح جلدي شديد أو بثور أو بقع حمراء على الجلد.</p><p>&bull; تفاعل حساسية شديد (يُدعى تأقًا) قد يُسبب صعوبة في التَّنفس أو صدمة.</p><p>&bull; تورم سريع في الجلد، يكون عادة حول العينين واللسان والحلق (وذمة وعائية).</p><p>ظهور بثور خطيرة بالجلد، والفم، والعينين، والأعضاء التناسلية</p><p>(متلازمة ستيفنز-جونسون).</p><p>&bull; إفراز ضار لهرمون يتحكم في كثافة البول.</p><p>&bull; تكسر ألياف العضلات وألم في العضلات (انحلال الربيدات).</p><p>&nbsp;</p><p>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة):</p><p>&bull; طفح جلدي مصحوب ببقع حمراء مختلفة (احمرار متعدد الأشكال).</p><p>&bull; تفاعلات حساسية خطيرة ومفاجئة مصحوبة بأعراض مثل: الحمى والبثور على الجلد وتقشر الجلد (انحلال البشرة النخري التَّسَمُّمِيّ).</p><p>&bull; قد تحدث أعراض انسحاب في حديثي الولادة الذين استخدمت أمهاتهم عقار سيكويت&trade; أثناء الحمل.</p><p>قد تسبب الفئة الدَّوائية التي ينتمي إليها عقار سيكويت&trade; مشاكل في النَّظم القلبي قد تكون خطيرة وقد تؤدي في الحالات الشَّديدة إلى الوفاة.</p><p>قد تلاحظ بعض الآثار الجانبية عند الخضوع لاختبار دم فقط. تشمل هذه الآثار الجانبية تغيرات في كميات بعض الدهون (الدهون الثلاثية وإجمالي الكوليسترول) أو في مستوى السكر بالدَّم أو تغيرات في مستوى هرمونات الغدة الدَّرقية في الدَّم أو زيادة في مستوى إنزيمات الكبد، أو انخفاض في عدد بعض أنواع خلايا الدَّم، أو انخفاض في كمية خلايا الدَّم الحمراء، أو زيادة في مستوى فسْفُوكيناز الكرياتين بالدَّم (مادة تُفرز في العضلات)، أو انخفاض في كمية الصوديوم في الدَّم أو زيادة في كمية هرمون البرولاكتين في الدَّم. تزايد في مستوى هرمون البرولاكين قد يُؤدي في حالات نادرة إلى التَّالي:</p><p>&bull; تورم الثدي لدى الرجال والنساء وإفراز لبن من الثدي بشكل غير متوقع لديهم.</p><p>&bull; انقطاع الدَّورة الشهرية لدى السيدات أو عدم انتظامها. قد يَطلب منك طبيبك الخضوع لاختبار دم من وقت لآخر.</p><p>&nbsp;</p><p>الآثار الجانبية الإضافية في الأطفال والمراهقين</p><p>قد تحدث الآثار الجانبية نفسها التي قد تصيب البالغين في الأطفال والمراهقين.</p><p>لُوحظت الآثار الجانبية التَّالية بشكل أغلب في الأطفال والمراهقين أو لم تلاحظ في البالغين:</p><p>&nbsp;</p><p>الآثار الجانبية الشَّائعة جدًّا (قد تُؤثر على أكثر من شخص 1 من بين كل 10&nbsp;أشخاص):</p><p>&bull; زيادة في كمية هرمون البرولاكتين في الدَّم. تزايد في مستوى هرمون البرولاكين قد يُؤدي في حالات نادرة إلى التَّالي:</p><p>- تورم الثدي لدى اليافعين من الذكور والإناث وإفراز لبن من الثدي بشكل غير متوقع لديهم.</p><p>- انقطاع الدَّورة الشهرية لدى اليافعين من الإناث أو عدم انتظامها.</p><p>&bull; ازدياد الشهية.</p><p>&bull; القيء.</p><p>&bull; حركة عضلات غير طبيعية. تشمل صعوبة في بدء حركة العضلات، والارتجاف، والشعور بالتململ أو التصلب بالعضلات غير مصحوب بألم.</p><p>&bull; ارتفاع في ضغط الدَّم.</p><p>&nbsp;</p><p>الآثار الجانبية الشائعة (قد تُؤثر في ما يصل إلى شخص 1 من بين كل 10&nbsp;أشخاص):</p><p>&bull; الشعور بالضعف، إغماء (قد يُؤدي إلى سقوط المريض).</p><p>&bull; انسداد الأنف.</p><p>&bull; شعور بالهياج.</p><p>&nbsp;</p><p>الإبلاغ عن الآثار الجانبية</p><p>إذا ظهرت لديك أية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي الخاص بك. بما في ذلك أيّة آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>5. كَيْفِية تَخْزِين عقار سيكويت&trade;</p><p>&nbsp;</p><p>&bull; يحفظ بعيدًا عن مُتناوَل و مرأى الأطفال.</p><p>&bull; لا تَستخدِم عقار سيكويت&trade; بعد انتهاء تاريخ الصلاحية المدون على العبوة بعد كلمة &quot;EXP&quot; .</p><p>&bull; يحفظ فى درجة حرارة لا تزيد عن 03 درجة مئوية.</p><p>&bull; لا تتخلَّص من أيّ أدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه التَّدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>6. محتويات العبوة ومعلومات أخرى</p><p>&nbsp;</p><p>ما هي محتويات عقار سيكويت&trade;؟</p><p>عقار سيكويت&trade; 25 ملجم:</p><p>يحتوي كل قرص مغلف على 25 ملجم من كوتايبين (في هيئة كوتايبين فومارات).</p><p>عقار سيكويت&trade; 100 ملجم:</p><p>يحتوي كل قرص مغلف على 100 ملجم من كوتايبين (في هيئة كوتايبين فومارات).</p><p>عقار سيكويت&trade; 200 ملجم:</p><p>يحتوي كل قرص مغلف على 200 ملجم من كوتايبين (في هيئة كوتايبين فومارات).</p><p>عقار سيكويت&trade; 300 ملجم:</p><p>يحتوي كل قرص مغلف على 300 ملجم من كوتايبين (في هيئة كوتايبين فومارات).</p><p>&nbsp;</p><p>المكونات الأخرى هي:</p><p>لب القرص:</p><p>لاكتوز أحادي الهيدرات، ثنائي هيدرات فوسفات الكالسيوم ثنائي القاعدة، سليلوز دقيق التَّبلور، بوفيدون، جليكولات نشا الصوديوم، ثاني أكسيد السيليكون الغروية، ستيرات الماغنسيوم.</p><p>الغلاف:</p><p>أوبادرى أبيض 03B28796 (هيبروميلوز، ثاني أكسيد التيتانيوم، بولي إيثيلين جلايكول).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>ما هو شكل عقار سيكويت&trade;؟ وما هي محتويات العبوة؟</p><p>عقار سيكويت&trade; 25 ملجم:</p><p>أقراص مغلفة بيضاء مستديرة، ثنائية التحدُّب، محفور عليها &#39;05&#39; على أحد جانبيها و &quot;JP&quot; على الجانب الآخر.</p><p>عقار سيكويت&trade; 100 ملجم:</p><p>أقراص مغلفة بيضاء مستديرة، ثنائية التحدُّب، محفور عليها &#39;128&#39; على أحد جانبيها و &quot;JP&quot; على الجانب الآخر.</p><p>عقار سيكويت&trade; 200 ملجم:</p><p>أقراص مغلفة بيضاء تشبه الكبسولة، ثنائية التحدُّب، محفور عليها &#39;129&#39; على أحد جانبيها و&quot;JP&quot; على الجانب الآخر.</p><p>عقار سيكويت&trade; 300 ملجم:</p><p>أقراص مغلفة بيضاء تشبه الكبسولة، ثنائية التحدُّب، محفور عليها &#39;130&#39; على أحد جانبيها و &quot;JP&quot; على الجانب الآخر.</p><p>&nbsp;</p><p>عقار سيكويت&trade; أقراص مغلفة متوفر بتركيزات 52 ملجم، 001 ملجم، 002 ملجم و 003 ملجم في عبوات تحتوى كلاً منها على 03 قرصاً.</p><p>&nbsp;</p><p>قد لا تكون كل العبوات مطروحة بالسوق.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>اسم وعنوان مالك رخصة التسويق و المصنع:</p><p>شركة مصنع جمجوم للأدوية،</p><p>جدة، المملكة العربية السعودية.</p><p>الهاتف: 6081111-12-966+&nbsp;&nbsp;&nbsp;&nbsp;</p><p>فاكس: 6081222-12-966+</p><p>الموقع الإلكتروني: www.jamjoompharma.com</p><p>&nbsp;</p><p>للإبلاغ عن أي أثار جانبيه:</p><p>&nbsp;</p><p>&bull; المملكة العربية السعودية:</p><p>المركز الوطني للتيقظ و السلامة الدوائية</p><p>فاكس: 7662-205-11-966+</p><p>للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات.</p><p>هاتف: 2038222-11-966+</p><p>تحويلة: 2317-2356-2353-2354-2334-2340</p><p>الهاتف المجاني: 8002490000&nbsp;&nbsp;</p><p>بريد إلكتروني:&nbsp; npc.drug@sfda.gov.sa</p><p>الموقع الالكتروني: www.sfda.gov.sa/npc</p><p>&nbsp;</p><p>&bull; دول الخليج الأخرى:</p><p>الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة في 08 /2016. رقم النسخة 01.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Sequit 25 mg Film Coated Tablets
- Sequit 100 mg Film Coated Tablets
- Sequit 200 mg Film Coated Tablets
- Sequit 300 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Sequit 25 mg F.C. Tablets contains 25 mg Quetiapine (as Quetiapine Fumarate)
Excipient: 5.00 mg Lactose Monohydrate per tablet.
- Sequit 100 mg F.C. Tablets contains 100 mg Quetiapine (as Quetiapine Fumarate)
Excipient: 20 mg Lactose Monohydrate per tablet.
- Sequit 200 mg F.C. Tablets contains 200 mg Quetiapine (as Quetiapine Fumarate)
Excipient: 40 mg Lactose Monohydrate per tablet
- Sequit 300 mg F.C. Tablets contains 300 mg Quetiapine (as Quetiapine Fumarate)
Excipient: 60 mg Lactose Monohydrate per tablet
For a full list of excipients, see Section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral Film Coated Tablet
- Sequit 25 mg F.C. Tablet sare white coloured, round, biconvex, film coated tablets,
debossed with '05' on one side and 'JP' on other side.
- Sequit 100 mg F.C. Tablets are white coloured, round, biconvex, film coated tablets,
debossed with '128' on one side and 'JP' on other side.
- Sequit 200 mg F.C. Tablet sare white coloured, capsule shaped, biconvex, film coated
tablets, debossed with '129' on one side and 'JP' on other side.
- Sequit 300 mg F.C. Tablets are white coloured, capsule shape, biconvex, film coated
tablets, debossed with '130' on one side and 'JP' on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sequit is indicated for:<br /> Treatment of Schizophrenia.<br /> Treatment of bipolar disorder:<br /> For the treatment of moderate to severe manic episodes in bipolar disorder<br /> For the treatment of major depressive episodes in bipolar disorder<br /> For the prevention of recurrence of manic or depressed episodes in patients with bipolar<br />disorder who previously responded to Quetiapine treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Different dosing schedules exist for each indication. It must therefore be ensured that patients<br />receive clear information on the appropriate dosage for their condition.<br />Sequit can be administered with or without food.<br />Adults:<br />For the treatment of schizophrenia<br />For the treatment of schizophrenia, Quetiapine should be administered twice a day. The total<br />daily dose for the first four days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3)<br />and 300 mg (Day 4) From Day 4 onwards, the dose should be titrated to the usual effective dose<br />of 300 to 450 mg/day. Depending on the clinical response and tolerability of the individual<br />patient, the dose may be adjusted within the range 150 to 750 mg/day.<br />For the treatment of moderate to severe manic episodes in bipolar disorder<br />For the treatment of manic episodes associated with bipolar disorder, Quetiapine should be<br />administered twice a day. The total daily dose for the first four days of therapy is 100 mg (Day<br />1), 200 mg (Day 2), 300 mg (Day 3) and 400 mg (Day 4). Further dosage adjustments up to 800<br />mg/day by Day 6 should be in increments of no greater than 200 mg/day.<br />The dose may be adjusted depending on clinical response and tolerability of the individual<br />patient, within the range of 200 to 800 mg/day. The usual effective dose is in the range of 400 to<br />800 mg/day.</p><p>For the treatment of major depressive episodes in bipolar disorder<br />Quetiapine should be administered once daily at bedtime. The total daily dose for the first four<br />days of therapy is 50 mg (Day 1), 100 mg (Day 2), 200 mg (Day 3) and 300 mg (Day 4). The<br />recommended daily dose is 300 mg. In clinical trials, no additional benefit was seen in the 600<br />mg group compared to the 300 mg group (see Section 5.1). Individual patients may benefit from<br />a 600 mg dose. Doses greater than 300 mg should be initiated by physicians experienced in<br />treating bipolar disorder. In individual patients, in the event of tolerance concerns, clinical trials<br />have indicated that dose reduction to a minimum of 200 mg could be considered.<br />For preventing recurrence in bipolar disorder<br />For preventing recurrence of manic, mixed or depressive episodes in bipolar disorder, patients<br />who have responded to Quetiapine for acute treatment of bipolar disorder should continue<br />therapy at the same dose. The dose may be adjusted depending on clinical response and<br />tolerability of the individual patient, within the range of 300 to 800 mg/day administered twice<br />daily. It is important that the lowest effective dose is used for maintenance therapy.<br />Elderly:<br />As with other antipsychotics, Quetiapine should be used with caution in the elderly, especially<br />during the initial dosing period. The rate of dose titration may need to be slower, and the daily<br />therapeutic dose lower, than that used in younger patients, depending on the clinical response<br />and tolerability of the individual patient. The mean plasma clearance of Quetiapine was reduced<br />by 30 - 50% in elderly subjects when compared to younger patients.<br />Efficacy and safety has not been evaluated in patients over 65 years with depressive episodes in<br />the framework of bipolar disorder.<br />Paediatric Population:<br />Quetiapine is not recommended for use in children and adolescents below 18 years of age, due to<br />a lack of data to support use in this age group. The available evidence from placebo-controlled<br />clinical trials is presented in Sections 4.4, 4.8, 5.1 and 5.2.</p><p>Renal Impairment:<br />Dosage adjustment is not necessary in patients with renal impairment.<br />Hepatic Impairment:<br />Quetiapine is extensively metabolised by the liver. Therefore, Quetiapine should be used with<br />caution in patients with known hepatic impairment, especially during the initial dosing period.<br />Patients with known hepatic impairment should be started with 25 mg/day. The dosage should be<br />increased daily with increments of 25 - 50 mg/day until an effective dosage, depending on the<br />clinical response and tolerability of the individual patient.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients of this product.
Concomitant administration of cytochrome P450 3A4 inhibitors, such as HIV-protease
inhibitors, azole-antifungal agents, erythromycin, clarithromycin and nefazodone, is
contraindicated. (See also Section 4.5.)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>As Quetiapine has several indications, the safety profile should be considered with respect to the<br />individual patient&#39;s diagnosis and the dose being administered.<br />Paediatric population:<br />Quetiapine is not recommended for use in children and adolescents below 18 years of age, due to<br />a lack of data to support use in this age group. Clinical trials with Quetiapine have shown that in<br />addition to the known safety profile identified in adults (see Section 4.8), certain adverse events<br />occurred at a higher frequency in children and adolescents compared to adults (increased<br />appetite, elevations in serum prolactin, vomiting, rhinitis and syncope), or may have different<br />implications for children and adolescents (extrapyramidal symptoms and irritability) and one was<br />identified that has not been previously seen in adult studies (increases in blood pressure).<br />Changes in thyroid function tests have also been observed in children and adolescents.</p><p>Furthermore, the long-term safety implications of treatment with Quetiapine on growth and<br />maturation have not been studied beyond 26 weeks. Long-term implications for cognitive and<br />behavioural development are not known.<br />In placebo-controlled clinical trials with children and adolescent patients, Quetiapine was<br />associated with an increased incidence of extrapyramidal symptoms (EPS) compared to placebo<br />in patients treated for schizophrenia, bipolar mania and bipolar depression (see Section 4.8).<br />Suicide/suicidal thoughts or clinical worsening:<br />Depression in bipolar disorder is associated with an increased risk of suicidal thoughts, self-harm<br />and suicide (suicide-related events). This risk persists until significant remission occurs. As<br />improvement may not occur during the first few weeks or more of treatment, patients should be<br />closely monitored until such improvement occurs. It is general clinical experience that the risk of<br />suicide may increase in the early stages of recovery.<br />In addition, physicians should consider the potential risk of suicide-related events after abrupt<br />cessation of Quetiapine treatment, due to the known risk factors for the disease being treated.<br />Other psychiatric conditions for which Quetiapine is prescribed can also be associated with an<br />increased risk of suicide related events. In addition, these conditions may be co-morbid with<br />major depressive episodes. The same precautions observed when treating patients with major<br />depressive episodes should therefore be observed when treating patients with other psychiatric<br />disorders.<br />Patients with a history of suicide related events, or those exhibiting a significant degree of<br />suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal<br />thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta<br />analysis of placebo controlled clinical trials of antidepressant drugs in adult patients with<br />psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants<br />compared to placebo in patients less than 25 years old.<br />Close supervision of patients and in particular those at high risk should accompany drug therapy<br />especially in early treatment and following dose changes. Patients (and caregivers of patients)<br />should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these<br />symptoms present.<br />In shorter-term placebo controlled clinical studies of patients with major depressive episodes in<br />bipolar disorder an increased risk of suicide-related events was observed in young adult patients<br />(younger than 25 years of age) who were treated with quetiapine as compared to those treated<br />with placebo (3.0% vs. 0%, respectively).<br />Metabolic Risk:<br />Given the observed risk for worsening of their metabolic profile, including changes in weight,<br />blood glucose (see hyperglycaemia) and lipids, which was seen in clinical studies, patients&#39;<br />metabolic parameters should be assessed at the time of treatment initiation and changes in these<br />parameters should be regularly controlled for during the course of treatment. Worsening in these<br />parameters should be managed as clinically appropriate (see also Section 4.8).<br />Extrapyramidal symptoms:<br />In placebo controlled clinical trials of adult patients Quetiapine was associated with an increased<br />incidence of extrapyramidal symptoms (EPS) compared to placebo in patients treated for major<br />depressive episodes in bipolar disorder (see Sections 4.8 and 5.1).<br />The use of Quetiapine has been associated with the development of akathisia, characterised by a<br />subjectively unpleasant or distressing restlessness and need to move often accompanied by an<br />inability to sit or stand still. This is most likely to occur within the first few weeks of treatment.<br />In patients who develop these symptoms, increasing the dose may be detrimental.<br />Tardive Dyskinesia:<br />If signs and symptoms of tardive dyskinesia appear, dose reduction or discontinuation of<br />Quetiapine should be considered. The symptoms of tardive dyskinesia can worsen or even arise<br />after discontinuation of treatment (see Section 4.8).<br />Somnolence and dizziness:<br />Quetiapine treatment has been associated with somnolence and related symptoms, such as<br />sedation (see Section 4.8). In clinical trials for treatment of patients with bipolar depression,<br />onset was usually within the first 3 days of treatment and was predominantly of mild to moderate intensity. Patients experiencing somnolence of severe intensity may require more frequent<br />contact for a minimum of 2 weeks from onset of somnolence, or until symptoms improve and<br />treatment discontinuation may need to be considered.<br />Orthostatic hypotension:<br />Quetiapine treatment has been associated with orthostatic hypotension and related dizziness (see<br />Section 4.8) which, like somnolence has onset usually during the initial dose-titration period.<br />This could increase the occurrence of accidental injury (fall), especially in the elderly population.<br />Therefore, patients should be advised to exercise caution until they are familiar with the potential<br />effects of the medication.<br />Quetiapine should be used with caution in patients with known cardiovascular disease,<br />cerebrovascular disease, or other conditions predisposing to hypotension. Dose reduction or<br />more gradual titration should be considered if orthostatic hypotension occurs, especially in<br />patients with underlying cardiovascular disease.<br />Sleep apnoea syndrome<br />Sleep apnoea syndrome has been reported in patients using Quetiapine. In patients receiving<br />concomitant central nervous system depressants and who have a history of or are at risk for sleep<br />apnoea, such as those who are overweight/obese or are male, Quetiapine should be used with<br />caution.<br />Seizures:<br />In controlled clinical trials there was no difference in the incidence of seizures in patients treated<br />with quetiapine or placebo. No data is available about the incidence of seizures in patients with a<br />history of seizure disorder. As with other antipsychotics, caution is recommended when treating<br />patients with a history of seizures (see Section 4.8).<br />Neuroleptic Malignant Syndrome:<br />Neuroleptic malignant syndrome has been associated with antipsychotic treatment, including<br />Quetiapine (see Section 4.8). Clinical manifestations include hyperthermia, altered mental status,<br />muscular rigidity, autonomic instability, and increased creatine phosphokinase. In such an event,<br />Quetiapine should be discontinued and appropriate medical treatment given.</p><p>Severe Neutropenia and agranulocytosis:<br />Severe neutropenia (neutrophil count &lt;0.5 X 109/L) has been reported in quetiapine clinical<br />trials. Most cases of severe neutropenia have occurred within a couple of months of starting<br />therapy with Quetiapine. There was no apparent dose relationship. During post-marketing<br />experience, some cases were fatal. Possible risk factors for neutropenia include pre-existing low<br />white blood cell count (WBC) and history of drug induced neutropenia. However, some cases<br />occurred in patients without pre-existing risk factors. Quetiapine should be discontinued in<br />patients with a neutrophil count &lt;1.0 X 109/L. Patients should be observed for signs and<br />symptoms of infection and neutrophil counts followed (until they exceed 1.5 X 109/L) (see<br />Section 5.1).<br />Neutropenia should be considered in patients presenting with infection or fever, particularly in<br />the absence of obvious predisposing factor(s), and should be managed as clinically appropriate.<br />Patients should be advised to immediately report the appearance of signs/symptoms consistent<br />with agranulocytosis or infection (e.g., fever, weakness, lethargy, or sore throat) at any time<br />during Quetiapine therapy. Such patients should have a WBC count and an absolute neutrophil<br />count (ANC) performed promptly, especially in the absence of predisposing factors.<br />Anti-cholinergic (muscarinic) effects:<br />Norquetiapine, an active metabolite of Quetiapine, has moderate to strong affinity for several<br />muscarinic receptor subtypes. This contributes to ADRs reflecting anti-cholinergic effects when<br />Quetiapine is used at recommended doses, when used concomitantly with other medications<br />having anti-cholinergic effects, and in the setting of overdose. Quetiapine should be used with<br />caution in patients receiving medications having anti-cholinergic (muscarinic) effects.<br />Quetiapine should be used with caution in patients with a current diagnosis or prior history of<br />urinary retention, clinically significant prostatic hypertrophy, intestinal obstruction or related<br />conditions, increased intraocular pressure or narrow angle glaucoma. (See Sections 4.5, 4.8, 5.1<br />and 4.9.)</p><p>Interactions:<br />See also Section 4.5.<br />Concomitant use of Quetiapine with a strong hepatic enzyme inducer such as carbamazepine or<br />phenytoin substantially decreases quetiapine plasma concentrations, which could affect the<br />efficacy of Quetiapine therapy. In patients receiving a hepatic enzyme inducer, initiation of<br />Quetiapine treatment should only occur if the physician considers that the benefits of Quetiapine<br />outweigh the risks of removing the hepatic enzyme inducer. It is important that any change in the<br />inducer is gradual, and if required, replaced with a non-inducer (e.g. sodium valproate).<br />Weight:<br />Weight gain has been reported in patients who have been treated with Quetiapine, and should be<br />monitored and managed as clinically appropriate as in accordance with utilised antipsychotic<br />guidelines (see Sections 4.8 and 5.1).<br />Hyperglycaemia:<br />Hyperglycaemia and/or development or exacerbation of diabetes occasionally associated with<br />ketoacidosis or coma has been reported rarely, including some fatal cases (see Section 4.8). In<br />some cases, a prior increase in body weight has been reported which may be a predisposing<br />factor. Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic<br />guidelines. Patients treated with any antipsychotic agent including quetiapine, should be<br />observed for signs and symptoms of hyperglycaemia (such as polydipsia, polyuria, polyphagia<br />and weakness) and patients with diabetes mellitus or with risk factors for diabetes mellitus<br />should be monitored regularly for worsening of glucose control. Weight should be monitored<br />regularly.<br />Lipids:<br />Increases in triglycerides, LDL and total cholesterol, and decreases in HDL cholesterol have<br />been observed in clinical trials with Quetiapine (see Section 4.8). Lipid changes should be<br />managed as clinically appropriate.<br />QT Prolongation:<br />In clinical trials and use in accordance with the SPC, Quetiapine was not associated with a<br />persistent increase in absolute QT intervals. In post-marketing, QT prolongation was reported with Quetiapine at the therapeutic doses (see Section 4.8) and in overdose (see Section 4.9). As<br />with other antipsychotics, caution should be exercised when Quetiapine is prescribed in patients<br />with cardiovascular disease or family history of QT prolongation. Also, caution should be<br />exercised when Quetiapine is prescribed either with medicines known to increase QT interval or<br />with concomitant neuroleptics, especially in the elderly, in patients with congenital long QT<br />syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia (see<br />Section 4.5).<br />Cardiomyopathy and Myocarditis:<br />Cardiomyopathy and myocarditis have been reported in clinical trials and during the postmarketing<br />experience, however, a causal relationship to Quetiapine has not been established.<br />Treatment with quetiapine should be reassessed in patients with suspected cardiomyopathy or<br />myocarditis.<br />Withdrawal:<br />Acute withdrawal symptoms such as insomnia, nausea, headache, diarrhoea, vomiting, dizziness<br />and irritability have been described after abrupt cessation of quetiapine. Gradual withdrawal over<br />a period of at least one to two weeks is advisable (See Section 4.8.)<br />Elderly patients with dementia-related psychosis:<br />Quetiapine is not approved for the treatment of dementia-related psychosis.<br />An approximately 3-fold increased risk of cerebrovascular adverse events has been seen in<br />randomised placebo controlled trials in the dementia population with some atypical<br />antipsychotics. The mechanism for this increased risk is not known. An increased risk cannot be<br />excluded for other antipsychotics or other patient populations. Quetiapine should be used with<br />caution in patients with risk factors for stroke.<br />In a meta-analysis of atypical antipsychotics, it has been reported that elderly patients with<br />dementia-related psychosis are at an increased risk of death compared to placebo. In two 10-<br />week placebo-controlled quetiapine studies in the same patient population (n=710); mean age: 83<br />years; range: 56-99 years) the incidence of mortality in quetiapine treated patients was 5.5%<br />versus 3.2% in the placebo group. The patients in these trials died from a variety of causes that<br />were consistent with expectations for this population.</p><p>Dysphagia:<br />Dysphagia (see Section 4.8) has been reported with quetiapine. Quetiapine should be used with<br />caution in patients at risk for aspiration pneumonia.<br />Constipation and intestinal obstruction:<br />Constipation represents a risk factor for intestinal obstruction. Constipation and intestinal<br />obstruction have been reported with quetiapine (see Section 4.8 Undesirable effects). This<br />includes fatal reports in patients who are at higher risk of intestinal obstruction, including those<br />that are receiving multiple concomitant medications that decrease intestinal motility and/or may<br />not report symptoms of constipation. Patients with intestinal obstruction/ileus should be managed<br />with close monitoring and urgent care.<br />Venous Thromboembolism (VTE):<br />Cases of venous thromboembolism (VTE) have been reported with antipsychotic drugs. Since<br />patients treated with antipsychotics often present with acquired risk factors for VTE, all possible<br />risk factors for VTE should be identified before and during treatment with quetiapine and<br />preventive measures undertaken.<br />Pancreatitis:<br />Pancreatitis has been reported in clinical trials and during post marketing experience. Among<br />post marketing reports, while not all cases were confounded by risk factors, many patients had<br />factors which are known to be associated with pancreatitis such as increased triglycerides (see<br />Section 4.4), gallstones, and alcohol consumption.<br />Additional information:<br />Quetiapine data in combination with divalproex or lithium in acute moderate to severe manic<br />episodes is limited; however, combination therapy was well tolerated (see Section 4.8 and 5.1).<br />The data showed an additive effect at week 3.<br />Lactose:<br />Quetiapine tablets contain lactose. Patients with rare hereditary problems of galactose<br />intolerance, the lapp lactase deficiency, or glucose-galactose malabsorption should not take this<br />medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given the primary central nervous system effects of quetiapine, quetiapine should be used with<br />caution in combination with other centrally acting medicinal products and alcohol.<br />Caution should be exercised treating patients receiving other medications having anti-cholinergic<br />(muscarinic) effects (see Section 4.4).<br />Cytochrome P450 (CYP) 3A4 is the enzyme that is primarily responsible for the cytochrome<br />P450 mediated metabolism of quetiapine. In an interaction study in healthy volunteers,<br />concomitant administration of quetiapine (dosage of 25 mg) with ketoconazole, a CYP3A4<br />inhibitor, caused a 5- to 8-fold increase in the AUC of quetiapine. On the basis of this,<br />concomitant use of quetiapine with CYP3A4 inhibitors is contraindicated. It is also not<br />recommended to consume grapefruit juice while on quetiapine therapy.<br />In a multiple dose trial in patients to assess the pharmacokinetics of quetiapine given before and<br />during treatment with carbamazepine (a known hepatic enzyme inducer), co-administration of<br />carbamazepine significantly increased the clearance of quetiapine. This increase in clearance<br />reduced systemic quetiapine exposure (as measured by AUC) to an average of 13% of the<br />exposure during administration of quetiapine alone; although a greater effect was seen in some<br />patients. As a consequence of this interaction, lower plasma concentrations can occur, which<br />could affect the efficacy of quetiapine therapy. Co-administration of quetiapine and phenytoin<br />(another microsomal enzyme inducer) caused a greatly increased clearance of quetiapine by<br />approx. 450%. In patients receiving a hepatic enzyme inducer, initiation of quetiapine treatment<br />should only occur if the physician considers that the benefits of quetiapine outweigh the risks of<br />removing the hepatic enzyme inducer. It is important that any change in the inducer is gradual,<br />and if required, replaced with a non-inducer (e.g. sodium valproate) (see Section 4.4).<br />The pharmacokinetics of quetiapine were not significantly altered by co-administration of the<br />antidepressants imipramine (a known CYP 2D6 inhibitor) or fluoxetine (a known CYP 3A4 and<br />CYP 2D6 inhibitor).<br />The pharmacokinetics of quetiapine were not significantly altered by co-administration of the<br />antipsychotics risperidone or haloperidol. Concomitant use of quetiapine and thioridazine caused<br />an increased clearance of Quetiapine with approx. 70%.<br />The pharmacokinetics of quetiapine were not altered following co-administration with<br />cimetidine.</p><p>The pharmacokinetics of lithium were not altered when co-administered with quetiapine.<br />In a 6-week, randomised, study of lithium and QUETIAPINE versus placebo and QUETIAPINE<br />in adult patients with acute mania, a higher incidence of extrapyramidal related events (in<br />particular tremor), somnolence, and weight gain were observed in the lithium add-on group<br />compared to the placebo add-on group (see Section 5.1).<br />The pharmacokinetics of sodium valproate and quetiapine were not altered to a clinically<br />relevant extent when co-administered. A retrospective study of children and adolescents who<br />received valproate, quetiapine, or both, found a higher incidence of leucopenia and neutropenia<br />in the combination group versus the monotherapy groups.<br />Formal interaction studies with commonly used cardiovascular medicinal products have not been<br />performed.<br />Caution should be exercised when quetiapine is used concomitantly with medicinal products<br />known to cause electrolyte imbalance or to increase QT interval.<br />There have been reports of false positive results in enzyme immunoassays for methadone and<br />tricyclic antidepressants in patients who have taken quetiapine. Confirmation of questionable<br />immunoassay screening results by an appropriate chromatographic technique is recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy<br />Pregnancy Category C:<br />The teratogenic potential of Quetiapine was studied in Wistar rats and Dutch Belted rabbits<br />dosed during the period of organogenesis. No evidence of a teratogenic effect was detected in<br />rats at doses of 25 to 200 mg/kg or 0.3 to 2.4 times the maximum human dose on an mg/m2 basis<br />or in rabbits at 25 to 100 mg/kg or 0.6 to 2.4 times the maximum human dose on a mg/m2 basis.<br />There was, however, evidence of embryo/fetal toxicity. Delays in skeletal ossification were<br />detected in rat fetuses at doses of 50 and 200 mg/kg (0.6 and 2.4 times the maximum human dose<br />on a mg/m2 basis) and in rabbits at 50 and 100 mg/kg (1.2 and 2.4 times the maximum human<br />dose on a mg/m2 basis). Fetal body weight was reduced in rat fetuses at 200 mg/kg and rabbit<br />fetuses at 100 mg/kg (2.4 times the maximum human dose on a mg/m2 basis for both species).</p><p>There was an increased incidence of a minor soft tissue anomaly (carpal/tarsal flexure) in rabbit<br />fetuses at a dose of 100 mg/kg (2.4 times the maximum human dose on a mg/m2 basis).<br />Evidence of maternal toxicity (i.e., decreases in body weight gain and/or death) was observed at<br />the high dose in the rat study and at all doses in the rabbit study. In a peri/postnatal reproductive<br />study in rats, no drug-related effects were observed at doses of 1, 10, and 20 mg/kg or 0.01, 0.12,<br />and 0.24 times the maximum human dose on a mg/m2 basis. However, in a preliminary<br />peri/postnatal study, there were increases in fetal and pup death, and decreases in mean litter<br />weight at 150 mg/kg, or 3.0 times the maximum human dose on a mg/m2 basis.<br />There are no adequate and well-controlled studies in pregnant women and quetiapine should be<br />used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br />First trimester<br />The moderate amount of published data from exposed pregnancies (i.e. between 300-1000<br />pregnancy outcomes), including individual reports and some observational studies do not suggest<br />an increased risk of malformations due to treatment. However, based on all available data, a<br />definite conclusion cannot be drawn. Animal studies have shown reproductive toxicity (see<br />Section 5.3). Therefore, quetiapine should only be used during pregnancy if the benefits justify<br />the potential risks.<br />Third trimester<br />Neonates exposed to antipsychotics (including quetiapine) during the third trimester of<br />pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms<br />that may vary in severity and duration following delivery. There have been reports of agitation,<br />hypertonia, hypotonia, tremor, somnolence, respiratory distress, or feeding disorder.<br />Consequently, newborns should be monitored carefully.</p><p>Breast-feeding<br />Based on very limited data from published reports on quetiapine excretion into human breast<br />milk, excretion of quetiapine at therapeutic doses appears to be inconsistent. Due to lack of<br />robust data, a decision must be made whether to discontinue breast-feeding or to discontinue<br />Quetiapine therapy taking into account the benefit of breast feeding for the child and the benefit<br />of therapy for the woman.<br />Fertility<br />The effects of quetiapine on human fertility have not been assessed. Effects related to elevated<br />prolactin levels were seen in rats, although these are not directly relevant to humans (see Section<br />5.3 preclinical data).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Given its primary central nervous system effects, quetiapine may interfere with activities<br />requiring mental alertness. Therefore, patients should be advised not to drive or operate<br />machinery, until individual susceptibility to this is known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported Adverse Drug Reactions (ADRs) with quetiapine (&ge;10%) are<br />somnolence, dizziness, headache, dry mouth, withdrawal (discontinuation) symptoms, elevations<br />in serum triglyceride levels, elevations in total cholesterol (predominantly LDL cholesterol),<br />decreases in HDL cholesterol, weight gain, decreased haemoglobin and extrapyramidal<br />symptoms.<br />The incidences of ADRs associated with quetiapine therapy, are tabulated below (Table 1)<br />according to the format recommended by the Council for International Organizations of Medical<br />Sciences (CIOMS III Working Group; 1995).<br />Table 1 ADRs associated with Quetiapine therapy<br />The frequencies of adverse events are ranked according to the following: Very common<br />(&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10,000, &lt;1/1000),<br />very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><table cellspacing="0" cellpadding="0" border="1" style="width:621.1pt"><tbody><tr><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:13.04%"><p><strong>SOC</strong></p></td><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:13.68%"><p><strong>Very Common</strong></p></td><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:18.56%"><p><strong>Common</strong></p></td><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:15.68%"><p><strong>Uncommon</strong></p></td><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:15.3%"><p><strong>Rare</strong></p></td><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:13.48%"><p><strong>Very Rare</strong></p></td><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:10.26%"><p><strong>Not known</strong></p></td></tr><tr><td style="border-color:#7b7b7b; height:45.75pt; vertical-align:top; width:13.04%"><p><em>Blood and lymphatic system disorders</em></p></td><td style="height:45.75pt; vertical-align:top; width:13.68%"><p>Decreased haemoglobin<sup>22</sup></p></td><td style="height:45.75pt; vertical-align:top; width:18.56%"><p>Leucopenia<sup>1, 28</sup>, decreased neutrophil count, eosinophils increased<sup>27</sup></p></td><td style="height:45.75pt; vertical-align:top; width:15.68%"><p>Neutropenia<sup>1</sup>, Thrombocytopenia, Anaemia, platelet count decreased<sup>13</sup></p></td><td style="height:45.75pt; vertical-align:top; width:15.3%"><p>Agranulocytosis<sup>26</sup></p></td><td style="height:45.75pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:34.55pt; vertical-align:top; width:13.04%"><p><em>Immune system disorders</em></p></td><td style="height:34.55pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:15.68%"><p>Hypersensitivity (including allergic skin reactions)</p></td><td style="height:34.55pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:13.48%"><p>Anaphylactic reaction<sup>5</sup></p></td><td style="height:34.55pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:68.7pt; vertical-align:top; width:13.04%"><p><em>Endocrine disorders</em></p></td><td style="height:68.7pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:68.7pt; vertical-align:top; width:18.56%"><p>Hyperprolactinaemia<sup>15</sup>, decreases in total T<sub>4</sub>&nbsp;<sup>24</sup>, decreases in free T<sub>4</sub>&nbsp;<sup>24</sup>, decreases in total T<sub>3</sub>&nbsp;<sup>24</sup>, increases in TSH&nbsp;<sup>24</sup></p></td><td style="height:68.7pt; vertical-align:top; width:15.68%"><p>Decreases in free T<sub>3</sub><sup>&nbsp;24</sup>, Hypothyroidism<sup>21</sup></p></td><td style="height:68.7pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:68.7pt; vertical-align:top; width:13.48%"><p>Inappropriate antidiuretic hormone secretion</p></td><td style="height:68.7pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:149.6pt; vertical-align:top; width:13.04%"><p><em>Metabolism and nutritional disorders</em></p></td><td style="height:149.6pt; vertical-align:top; width:13.68%"><p>Elevations in serum triglyceride levels<sup>10, 30</sup></p><p>Elevations in total cholesterol (predominantly LDL cholesterol)<sup>11, 30</sup></p><p>Decreases in HDL cholesterol&nbsp;<sup>17,30</sup>, Weight gain&nbsp;<sup>8,30</sup></p></td><td style="height:149.6pt; vertical-align:top; width:18.56%"><p>Increased appetite, blood glucose increased to hyperglycaemic levels<sup>6, 30</sup></p></td><td style="height:149.6pt; vertical-align:top; width:15.68%"><p>Hyponatraemia<sup>19</sup>, Diabetes Mellitus<sup>1, 5</sup>&nbsp;Exacerbation of pre-existing diabetes</p></td><td style="height:149.6pt; vertical-align:top; width:15.3%"><p>Metabolic syndrome<sup>29</sup></p></td><td style="height:149.6pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:149.6pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:69.15pt; vertical-align:top; width:13.04%"><p><em>Psychiatric disorders</em></p></td><td style="height:69.15pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:69.15pt; vertical-align:top; width:18.56%"><p>Abnormal dreams and nightmares, Suicidal ideation and suicidal behaviour<sup>20</sup></p></td><td style="height:69.15pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:69.15pt; vertical-align:top; width:15.3%"><p>Somnambulism and related reactions such as sleep talking and sleep related eating disorder</p></td><td style="height:69.15pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:69.15pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:57.45pt; vertical-align:top; width:13.04%"><p><em>Nervous system disorders</em></p></td><td style="height:57.45pt; vertical-align:top; width:13.68%"><p>Dizziness<sup>4, 16</sup>, somnolence&nbsp;<sup>2, 16</sup>, headache, Extrapyramidal symptoms<sup>1, 21</sup></p></td><td style="height:57.45pt; vertical-align:top; width:18.56%"><p>Dysarthria</p></td><td style="height:57.45pt; vertical-align:top; width:15.68%"><p>Seizure<sup>1</sup>, Restless legs syndrome, Tardive dyskinesia<sup>1, 5</sup>, Syncope<sup>4,16</sup></p></td><td style="height:57.45pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:22.85pt; vertical-align:top; width:13.04%"><p><em>Cardiac disorders</em></p></td><td style="height:22.85pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:22.85pt; vertical-align:top; width:18.56%"><p>Tachycardia<sup>4</sup>, Palpitations<sup>23</sup></p></td><td style="height:22.85pt; vertical-align:top; width:15.68%"><p>QT prolongation&nbsp;<sup>1, 12, 18</sup>, Bradycardia<sup>32</sup></p></td><td style="height:22.85pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:22.85pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:22.85pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:11.65pt; vertical-align:top; width:13.04%"><p><em>Eye disorders</em></p></td><td style="height:11.65pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:11.65pt; vertical-align:top; width:18.56%"><p>Vision blurred</p></td><td style="height:11.65pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:11.65pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:11.65pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:11.65pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:22.85pt; vertical-align:top; width:13.04%"><p><em>Vascular disorders</em></p></td><td style="height:22.85pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:22.85pt; vertical-align:top; width:18.56%"><p>Orthostatic hypotension<sup>4, 16</sup></p></td><td style="height:22.85pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:22.85pt; vertical-align:top; width:15.3%"><p>Venous thromboembolism<sup>1</sup></p></td><td style="height:22.85pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:22.85pt; vertical-align:top; width:10.26%"><p>Stroke<sup>33</sup></p></td></tr><tr><td style="border-color:#7b7b7b; height:45.75pt; vertical-align:top; width:13.04%"><p><em>Respiratory, thoracic and mediastinal disorder</em></p></td><td style="height:45.75pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:18.56%"><p>Dyspnoea&nbsp;<sup>23</sup></p></td><td style="height:45.75pt; vertical-align:top; width:15.68%"><p>Rhinitis</p></td><td style="height:45.75pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:34.55pt; vertical-align:top; width:13.04%"><p><em>Gastrointestinal disorders</em></p></td><td style="height:34.55pt; vertical-align:top; width:13.68%"><p>Dry mouth</p></td><td style="height:34.55pt; vertical-align:top; width:18.56%"><p>Constipation, dyspepsia, vomiting<sup>25</sup></p></td><td style="height:34.55pt; vertical-align:top; width:15.68%"><p>Dysphagia<sup>7</sup></p></td><td style="height:34.55pt; vertical-align:top; width:15.3%"><p>Pancreatitis<sup>1</sup>, Intestinal obstruction/Ileus</p></td><td style="height:34.55pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:57.45pt; vertical-align:top; width:13.04%"><p><em>Hepato-biliary disorders</em></p></td><td style="height:57.45pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:18.56%"><p>Elevations in serum alanine aminotransferase (ALT)<sup>3,</sup>&nbsp;Elevations in gamma-GT levels<sup>3</sup></p></td><td style="height:57.45pt; vertical-align:top; width:15.68%"><p>Elevations in serum aspartate aminotransferase (AST)<sup>3</sup></p></td><td style="height:57.45pt; vertical-align:top; width:15.3%"><p>Jaundice<sup>5</sup>, Hepatitis</p></td><td style="height:57.45pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:137.85pt; vertical-align:top; width:13.04%"><p><em>Skin and subcutaneous tissue disorders</em></p></td><td style="height:137.85pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:137.85pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:137.85pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:137.85pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:137.85pt; vertical-align:top; width:13.48%"><p>Angioedema<sup>5</sup>, Stevens-Johnson syndrome<sup>5</sup></p></td><td style="height:137.85pt; vertical-align:top; width:10.26%"><p>Toxic Epidermal Necrolysis, Erythema Multiforme, Drug Rash with Eosinophilia and Systemic Symptoms (DRESS)</p></td></tr><tr><td style="border-color:#7b7b7b; height:34.55pt; vertical-align:top; width:13.04%"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="height:34.55pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:13.48%"><p>Rhabdomyolysis</p></td><td style="height:34.55pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:34.55pt; vertical-align:top; width:13.04%"><p><em>Renal and urinary disorders</em></p></td><td style="height:34.55pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:15.68%"><p>Urinary retention</p></td><td style="height:34.55pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:45.75pt; vertical-align:top; width:13.04%"><p><em>Pregnancy, puerperium and perinatal conditions</em></p></td><td style="height:45.75pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:15.3%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:10.26%"><p>Drug withdrawal syndrome neonatal<sup>31</sup></p></td></tr><tr><td style="border-color:#7b7b7b; height:57.45pt; vertical-align:top; width:13.04%"><p><em>Reproductive system and breast disorders</em></p></td><td style="height:57.45pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:15.68%"><p>Sexual dysfunction</p></td><td style="height:57.45pt; vertical-align:top; width:15.3%"><p>Priapism, galactorrhoea, breast swelling, menstrual disorder</p></td><td style="height:57.45pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:57.45pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:45.75pt; vertical-align:top; width:13.04%"><p><em>General disorders and administration site conditions</em></p></td><td style="height:45.75pt; vertical-align:top; width:13.68%"><p>Withdrawal (discontinuation) symptoms<sup>1, 9</sup></p></td><td style="height:45.75pt; vertical-align:top; width:18.56%"><p>Mild asthenia, peripheral oedema, irritability, pyrexia</p></td><td style="height:45.75pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:15.3%"><p>Neuroleptic malignant syndrome<sup>1</sup>, hypothermia</p></td><td style="height:45.75pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:45.75pt; vertical-align:top; width:10.26%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; height:34.55pt; vertical-align:top; width:13.04%"><p><em>Investigations</em></p></td><td style="height:34.55pt; vertical-align:top; width:13.68%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:18.56%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:15.68%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:15.3%"><p>Elevations in blood creatine phosphokinase<sup>14</sup></p></td><td style="height:34.55pt; vertical-align:top; width:13.48%">&nbsp;</td><td style="height:34.55pt; vertical-align:top; width:10.26%">&nbsp;</td></tr></tbody></table><p>1. See Section 4.4.<br />2. Somnolence may occur, usually during the first two weeks of treatment and generally resolves<br />with the continued administration of quetiapine.<br />3. Asymptomatic elevations (shift from normal to &gt;3X ULN at any time) in serum transaminase<br />(ALT, AST) or gamma-GT levels have been observed in some patients administered quetiapine.<br />These elevations were usually reversible on continued quetiapine treatment.<br />4. As with other antipsychotics with alpha1 adrenergic blocking activity, quetiapine may<br />commonly induce orthostatic hypotension, associated with dizziness, tachycardia and, in some<br />patients, syncope, especially during the initial dose-titration period. (see Section 4.4).<br />5. Calculation of Frequency for these ADR&#39;s have been taken from post-marketing data only.<br />6. Fasting blood glucose &ge;126 mg/dL (&ge;7.0 mmol/L) or a non fasting blood glucose &ge;200mg/dL<br />(&ge;11.1 mmol/L) on at least one occasion.<br />7. An increase in the rate of dysphagia with quetiapine vs. placebo was only observed in the<br />clinical trials in bipolar depression.<br />8. Based on &gt;7% increase in body weight from baseline. Occurs predominantly during the early<br />weeks of treatment in adults.<br />9. The following withdrawal symptoms have been observed most frequently in acute placebocontrolled,<br />monotherapy clinical trials, which evaluated discontinuation symptoms: insomnia,<br />nausea, headache, diarrhoea, vomiting, dizziness, and irritability. The incidence of these<br />reactions had decreased significantly after 1 week post-discontinuation.</p><p>10. Triglycerides &ge;200 mg/dL (&ge;2.258 mmol/L) (patients &ge;18 years of age) or &ge;150 mg/dL<br />(&ge;1.694 mmol/L) (patients &lt;18 years of age) on at least one occasion.<br />11. Cholesterol &ge;240 mg/dL (&ge;6.2064 mmol/L) (patients &ge;18 years of age) or &ge;200 mg/dL<br />(&ge;5.172 mmol/L) (patients &lt;18 years of age) on at least one occasion. An increase in LDL<br />cholesterol of &ge;30 mg/dL (&ge;0.769 mmol/L) has been very commonly observed. Mean change<br />among patients who had this increase was 41.7 mg/dL (&ge;1.07 mmol/L).<br />12. See text below.<br />13. Platelets &le;100 x 109/L on at least one occasion.<br />14. Based on clinical trial adverse event reports of blood creatine phosphokinase increase not<br />associated with neuroleptic malignant syndrome.<br />15. Prolactin levels (patients &gt;18 years of age): &gt;20 &mu;g/L (&gt;869.56 pmol/L) males; &gt;30 &mu;g/L<br />(&gt;1304.34 pmol/L) females at any time.<br />16. May lead to falls.<br />17. HDL cholesterol: &lt;40 mg/dL (1.025 mmol/L) males; &lt;50 mg/dL (1.282 mmol/L) females at<br />any time.<br />18. Incidence of patients who have a QTc shift from &lt;450 msec to &ge;450 msec with a &ge;30 msec<br />increase. In placebo-controlled trials with quetiapine the mean change and the incidence of<br />patients who have a shift to a clinically significant level is similar between quetiapine and<br />placebo.<br />19. Shift from &gt;132 mmol/L to &le;132 mmol/L on at least one occasion.<br />20. Cases of suicidal ideation and suicidal behaviours have been reported during quetiapine<br />therapy or early after treatment discontinuation (See sections 4.4 and 5.1)<br />21. See Section 5.1.<br />22. Decreased haemoglobin to &le;13 g/dL (8.07 mmol/L) males, &le;12 g/dL (7.45 mmol/L) females<br />on at least one occasion occurred in 11% of quetiapine patients in all trials including open label<br />extensions. For these patients, the mean maximum decrease in haemoglobin at any time was &ndash;<br />1.50 g/dL.<br />23. These reports often occurred in the setting of tachycardia, dizziness, orthostatic hypotension<br />and/or underlying cardiac/respiratory disease.</p><p>24. Based on shifts from normal baseline to potentially clinically important value at any time<br />post-baseline in all trials. Shifts in total T4, free T4, total T3 and free T3 are defined as &lt;0.8 x<br />LLN (pmol/L) and shift in TSH is &gt; 5 mIU/L at any time.<br />25. Based upon the increased rate of vomiting in elderly patients (&ge;65 years of age).<br />26. Based on shift in neutrophils from &gt; =1.5 x 10^9L at baseline to &lt;0.5 x 10^9/L at any time<br />during treatment and based on patients with severe neutropenia (&lt;0.5 x 109/L) and infection<br />during all quetiapine clinical trials (see Section 4.4).<br />27. Based on shifts from normal baseline to potentially clinically important value at any time<br />post-baseline in all trials. Shifts in eosinophils are defined as &gt;1 x 10^9 cells/L at any time.<br />28. Based on shifts from normal baseline to potentially clinically important value at any time<br />post-baseline in all trials. Shifts in WBCs are defined as &le;3 x 10^9 cells/L at any time.<br />29. Based on adverse event reports of metabolic syndrome from all clinical trials with quetiapine.<br />30. In some patients, a worsening of more than one of the metabolic factors of weight, blood<br />glucose and lipids was observed in clinical studies (see Section 4.4).<br />31. See Section 4.6<br />32. May occur at or near initiation of treatment and be associated with hypotension and/or<br />syncope. Frequency based on adverse event reports of bradycardia and related events in all<br />clinical trials with quetiapine.<br />Cases of QT prolongation, ventricular arrhythmia, sudden unexplained death, cardiac arrest and<br />torsades de pointes have been reported with the use of neuroleptics and are considered class<br />effects.<br />Paediatric population<br />The same ADRs described above for adults should be considered for children and adolescents.<br />The following table summarises ADRs that occur in a higher frequency category in children and<br />adolescent patients (10-17 years of age) than in the adult population or ADRs that have not been<br />identified in the adult population.</p><p>Table 2 ADRs in children and adolescents associated with Quetiapine therapy that occur in<br />a higher frequency than adults, or not identified in the adult population<br />The frequencies of adverse events are ranked according to the following: Very common (&gt;1/10),<br />common (&gt;1/100, &lt;1/10), uncommon (&gt;1/1000, &lt;1/100), rare (&gt;1/10,000, &lt;1/1000) and very<br />rare (&lt;1/10,000).</p><table cellspacing="0" cellpadding="0" border="1" style="width:518.25pt"><tbody><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><strong>SOC</strong></p></td><td style="border-color:#7b7b7b; vertical-align:top; width:29.0%"><p><strong>Very Common</strong></p></td><td style="border-color:#7b7b7b; vertical-align:top; width:16.0%"><p><strong>Common</strong></p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>Endocrine disorders</em></p></td><td style="vertical-align:top; width:29.0%"><p>Elevations in prolactin<sup>1</sup></p></td><td style="vertical-align:top; width:16.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>Metabolism and nutritional disorders</em></p></td><td style="vertical-align:top; width:29.0%"><p>Increased appetite</p></td><td style="vertical-align:top; width:16.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>Nervous system disorders</em></p></td><td style="vertical-align:top; width:29.0%"><p>Extrapyramidal symptoms<sup>3, 4</sup></p></td><td style="vertical-align:top; width:16.0%"><p>Syncope</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>Vascular disorders</em></p></td><td style="vertical-align:top; width:29.0%"><p>Increases in blood pressure<sup>2</sup></p></td><td style="vertical-align:top; width:16.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td><td style="vertical-align:top; width:29.0%">&nbsp;</td><td style="vertical-align:top; width:16.0%"><p>Rhinitis</p></td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>Gastrointestinal disorders</em></p></td><td style="vertical-align:top; width:29.0%"><p>Vomiting</p></td><td style="vertical-align:top; width:16.0%">&nbsp;</td></tr><tr><td style="border-color:#7b7b7b; vertical-align:top; width:55.0%"><p><em>General disorders and administration site conditions</em></p></td><td style="vertical-align:top; width:29.0%">&nbsp;</td><td style="vertical-align:top; width:16.0%"><p>Irritability<sup>3</sup></p></td></tr></tbody></table><p>1. Prolactin levels (patients &lt; 18 years of age): &gt;20 &mu;g/L (&gt;869.56 pmol/L) males; &gt;26 &mu;g/L<br />(&gt;1130.428 pmol/L) females at any time. Less than 1% of patients had an increase to a prolactin<br />level &gt;100 &mu;g/L.<br />2. Based on shifts above clinically significant thresholds (adapted from the National Institutes of<br />Health criteria) or increases &gt;20 mmHg for systolic or &gt;10 mmHg for diastolic blood pressure at<br />any time in two acute (3-6 weeks) placebo-controlled trials in children and adolescents.<br />3. Note: The frequency is consistent to that observed in adults, but might be associated with<br />different clinical implications in children and adolescents as compared to adults.<br />4. See Section 5.1.</p><p>Reporting of suspected adverse reactions<br />To report any side effect(s):<br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662.<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />In general, reported signs and symptoms were those resulting from an exaggeration of the active<br />substance&#39;s known pharmacological effects, ie, drowsiness and sedation, tachycardia,<br />hypotension and anti-cholinergic effects.<br />Overdose could lead to QT-prolongation, seizures, status epilepticus, rhabdomyolysis,<br />respiratory depression, urinary retention, confusion, delirium and/or agitation, coma and death.<br />Patients with pre-existing severe cardiovascular disease may be at an increased risk of the effects<br />of overdose. (see Section 4.4, Orthostatic hypotension).<br />Management of overdose<br />There is no specific antidote to Quetiapine. In cases of severe signs, the possibility of multiple<br />drug involvement should be considered, and intensive care procedures are recommended,<br />including establishing and maintaining a patent airway, ensuring adequate oxygenation and<br />ventilation, and monitoring and support of the cardiovascular system.<br />Based on public literature, patients with delerium and agitation and a clear anti-cholinergic<br />syndrome may be treated with physostigmine, 1-2 mg (under continuous ECG monitoring). This<br />is not recommended as standard treatment, because of potential negative effect of physostigmine<br />on cardiac conductance. Physostigmine may be used if there are no ECG aberrations. Do not use<br />physostigmine in case of dysrhythmias, any degree of heart block or QRS-widening.</p><p>Whilst the prevention of absorption in overdose has not been investigated, gastric lavage can be<br />indicated in severe poisonings and if possible to perform within one hour of ingestion. The<br />administration of activated charcoal should be considered.<br />In cases of quetiapine overdose, refractory hypotension should be treated with appropriate<br />measures such as intravenous fluids and/or sympathomimetic agents. Epinephrine and dopamine<br />should be avoided, since beta stimulation may worsen hypotension in the setting of quetiapineinduced<br />alpha blockade.<br />Close medical supervision and monitoring should be continued until the patient recovers.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antipsychotics<br />ATC code: N05A H04<br />Mechanism of action:<br />Quetiapine is an atypical antipsychotic agent. Quetiapine and the active human plasma<br />metabolite, norquetiapine interact with a broad range of neurotransmitter receptors. Quetiapine<br />and norquetiapine exhibit affinity for brain serotonin (5HT2) and dopamine D1- and D2-<br />receptors. It is this combination of receptor antagonism with a higher selectivity for 5HT2<br />relative to D2- receptors, which is believed to contribute to the clinical antipsychotic properties<br />and low extrapyramidal side effect (EPS) liability of Quetiapine compared to typical<br />antipsychotics. Quetiapine and norquetiapine have no appreciable affinity at benzodiazepine<br />receptors but high affinity at histaminergic and adrenergic alpha1 receptors and moderate affinity<br />at adrenergic alpha2 receptors. Quetiapine also has low or no affinity for muscarinic receptors,<br />while norquetiapine has moderate to high affinity at several muscarinic receptors, which may<br />explain anti-cholinergic (muscarinic) effects. Inhibition of NET and partial agonist action at<br />5HT1A sites by norquetiapine may contribute to Quetiapine&#39;s therapeutic efficacy as an<br />antidepressant.</p><p>Pharmacodynamic effects:<br />Quetiapine is active in tests for antipsychotic activity, such as conditioned avoidance. It also<br />blocks the action of dopamine agonists, measured either behaviourally or electrophysiologically,<br />and elevates dopamine metabolite concentrations, a neurochemical index of D2-receptor<br />blockade.<br />In pre-clinical tests predictive of EPS, quetiapine is unlike typical antipsychotics and has an<br />atypical profile. Quetiapine does not produce dopamine D2 receptor supersensitivity after chronic<br />administration. Quetiapine produces only weak catalepsy at effective dopamine D2 receptor<br />blocking doses. Quetiapine demonstrates selectivity for the limbic system by producing<br />depolarisation blockade of the mesolimbic but not the nigrostriatal dopamine-containing<br />neurones following chronic administration. Quetiapine exhibits minimal dystonic liability in<br />haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration (see<br />Section 4.8.)<br />Clinical efficacy:<br />Schizophrenia<br />In three placebo-controlled clinical trials, in patients with schizophrenia, using variable doses of<br />quetiapine, there were no differences between the Quetiapine and placebo treatment groups in<br />the incidence of EPS or concomitant use of anti-cholinergics. A placebo-controlled trial<br />evaluating fixed doses of quetiapine across the range of 75 to 750 mg/day showed no evidence of<br />an increase in EPS or the use of concomitant anti-cholinergics. The long-term efficacy of<br />Quetiapine IR in prevention of schizophrenic relapses has not been verified in blinded clinical<br />trials. In open label trials, in patients with schizophrenia, quetiapine was effective in maintaining<br />the clinical improvement during continuation therapy in patients who showed an initial treatment<br />response, suggesting some long-term efficacy.<br />Bipolar Disorder<br />In four placebo-controlled clinical trials, evaluating doses of Quetiapine up to 800 mg/day for the<br />treatment of moderate to severe manic episodes, two each in monotherapy and as combination<br />therapy to lithium or divalproex, , there were no differences between the Quetiapine and placebo<br />treatment groups in the incidence of EPS or concomitant use of anti-cholinergics.</p><p>In the treatment of moderate to severe manic episodes, Quetiapine demonstrated superior<br />efficacy to placebo in reduction of manic symptoms at 3 and 12 weeks, in two monotherapy<br />trials. There are no data from long-term studies to demonstrate Quetiapine&#39;s effectiveness in<br />preventing subsequent manic or depressive episodes. Quetiapine data in combination with<br />divalproex or lithium in acute moderate to severe manic episodes at 3 and 6 weeks is limited;<br />however, combination therapy was well tolerated. The data showed an additive effect at week 3.<br />A second study did not demonstrate an additive effect at week 6.<br />The mean last week median dose of Quetiapine in responders was approximately 600 mg/day<br />and approximately 85% of the responders were in the dose range of 400 to 800 mg/day.<br />In 4 clinical trials with a duration of 8 weeks in patients with moderate to severe depressive<br />episodes in bipolar I or bipolar II disorder, Quetiapine IR 300 mg and 600 mg was significantly<br />superior to placebo treated patients for the relevant outcome measures: mean improvement on<br />the MADRS and for response defined as at least a 50% improvement in MADRS total score<br />from baseline. There was no difference in magnitude of effect between the patients who received<br />300 mg Quetiapine IR and those who received 600 mg dose.<br />In the continuation phase in two of these studies, it was demonstrated that long-term treatment,<br />of patients who responded on Quetiapine IR 300 or 600 mg, was efficacious compared to<br />placebo treatment with respect to depressive symptoms, but not with regard to manic symptoms.<br />In two recurrence prevention studies evaluating Quetiapine in combination with mood<br />stabilizers, in patients with manic, depressed or mixed mood episodes, the combination with<br />Quetiapine was superior to mood stabilizers monotherapy in increasing the time to recurrence of<br />any mood event (manic, mixed or depressed). Quetiapine was administered twice-daily totalling<br />400 mg to 800 mg a day as combination therapy to lithium or valproate.<br />In a 6-week, randomised, study of lithium and QUETIAPINE versus placebo and QUETIAPINE<br />in adult patients with acute mania, the difference in YMRS mean improvement between the<br />lithium add-on group and the placebo add-on group was 2.8 points and the difference in %<br />responders (defined as 50% improvement from baseline on the YMRS) was 11% (79% in the<br />lithium add-on group vs. 68% in the placebo add-on group).</p><p>In one long-term study (up to 2 years treatment) evaluating recurrence prevention in patients<br />with manic, depressed or mixed mood episodes quetiapine was superior to placebo in increasing<br />the time to recurrence of any mood event (manic, mixed or depressed), in patients with bipolar I<br />disorder. The number of patients with a mood event was 91 (22.5%) in the quetiapine group, 208<br />(51.5%) in the placebo group and 95 (26.1%) in the lithium treatment groups respectively. In<br />patients who responded to quetiapine, when comparing continued treatment with quetiapine to<br />switching to lithium, the results indicated that a switch to lithium treatment does not appear to be<br />associated with an increased time to recurrence of a mood event.<br />Clinical trials have demonstrated that Quetiapine is effective in schizophrenia and mania when<br />given twice a day, although quetiapine has a pharmacokinetic half-life of approximately 7 hours.<br />This is further supported by the data from a positron emission tomography (PET) study, which<br />identified that for quetiapine, 5HT2- and D2-receptor occupancy are maintained for up to 12<br />hours. The safety and efficacy of doses greater than 800 mg/day have not been evaluated.<br />Clinical safety<br />In short-term, placebo-controlled clinical trials in schizophrenia and bipolar mania the<br />aggregated incidence of extrapyramidal symptoms was similar to placebo (schizophrenia: 7.8%<br />for quetiapine and 8.0% for placebo; bipolar mania: 11.2% for quetiapine and 11.4% for<br />placebo). Higher rates of extrapyramidal symptoms were seen in quetiapine treated patients<br />compared to those treated with placebo in short-term, placebo-controlled clinical trials in MDD<br />and bipolar depression. In short-term, placebo-controlled bipolar depression trials the aggregated<br />incidence of extrapyramidal symptoms was 8.9% for quetiapine compared to 3.8% for placebo.<br />In short-term, placebo-controlled monotherapy clinical trials in major depressive disorder the<br />aggregated incidence of extrapyramidal symptoms was 5.4% for Quetiapine and 3.2% for<br />placebo. In a short-term placebo-controlled monotherapy trial in elderly patients with major<br />depressive disorder, the aggregated incidence of extrapyramidal symptoms was 9.0% for<br />Quetiapine and 2.3% for placebo. In both bipolar depression and MDD, the incidence of the<br />individual adverse events (eg, akathisia, extrapyramidal disorder, tremor, dyskinesia, dystonia,<br />restlessness, muscle contractions involuntary, psychomotor hyperactivity and muscle rigidity)<br />did not exceed 4% in any treatment group.</p><p>In short term, fixed dose (50mg/d to 800 mg/d), placebo-controlled studies (ranging from 3 to 8<br />weeks), the mean weight gain for quetiapine-treated patients ranged from 0.8 kg for the 50 mg<br />daily dose to 1.4 kg for the 600 mg daily dose (with lower gain for the 800 mg daily dose),<br />compared to 0.2 kg for the placebo treated patients. The percentage of quetiapine treated patients<br />who gained &ge;7% of body weight ranged from 5.3% for the 50 mg daily dose to 15.5% for the<br />400 mg daily dose (with lower gain for the 600 and 800 mg daily doses), compared to 3.7% for<br />placebo treated patients.<br />A 6-week, randomised, study of lithium and QUETIAPINE versus placebo and QUETIAPINE in<br />adult patients with acute mania indicated that the combination of QUETIAPINE with lithium<br />leads to more adverse events (63% versus 48% in QUETIAPINE in combination with placebo).<br />The safety results showed a higher incidence of extrapyramidal symptoms reported in 16.8% of<br />patients in the lithium add-on group and 6.6% in the placebo add-on group, the majority of which<br />consisted of tremor, reported in 15.6% of the patients in the lithium add-on group and 4.9% in<br />the placebo add-on group. The incidence of somnolence was higher in the QUETIAPINE with<br />lithium add-on group (12.7%) compared to the QUETIAPINE with the placebo add-on group<br />(5.5%). In addition, a higher percentage of patients treated in the lithium add-on group (8.0%)<br />had weight gain (&ge;7%) at the end of treatment compared to patients in the placebo add-on group<br />(4.7%).<br />Longer term relapse prevention trials had an open label period (ranging from 4 to 36 weeks)<br />during which patients were treated with quetiapine, followed by a randomized withdrawal period<br />during which patients were randomized to quetiapine or placebo. For patients who were<br />randomized to quetiapine, the mean weight gain during the open label period was 2.56 kg, and<br />by week 48 of the randomized period, the mean weight gain was 3.22 kg, compared to open label<br />baseline. For patients who were randomized to placebo, the mean weight gain during the open<br />label period was 2.39 kg, and by week 48 of the randomized period the mean weight gain was<br />0.89 kg, compared to open label baseline.<br />In placebo-controlled studies in elderly patients with dementia-related psychosis, the incidence<br />of cerebrovascular adverse events per 100 patient years was not higher in quetiapine-treated<br />patients than in placebo-treated patients.</p><p>In all short-term placebo-controlled monotherapy trials in patients with a baseline neutrophil<br />count &ge;1.5 X 109/L, the incidence of at least one occurrence of a shift to neutrophil count &lt;1.5 X<br />109/L, was 1.9% in patients treated with quetiapine compared to 1.5% in placebo-treated<br />patients. The incidence of shifts to &gt;0.5-&lt;1.0 x 109/L was the same (0.2%) in patients treated<br />with quetiapine as with placebo-treated patients. In all clinical trials (placebo-controlled, openlabel,<br />active comparator) in patients with a baseline neutrophil count &ge;1.5 X 109/L, the incidence<br />of at least one occurrence of a shift to neutrophil count &lt;1.5 x 109/L was 2.9% and to &lt;0.5 X<br />109/L was 0.21% in patients treated with quetiapine.<br />Quetiapine treatment was associated with dose-related decreases in thyroid hormone levels. The<br />incidences of shifts in TSH was 3.2% for quetiapine versus 2.7% for placebo. The incidence of<br />reciprocal, potentially clinically significant shifts of both T3 or T4 and TSH in these trials were<br />rare, and the observed changes in thyroid hormone levels were not associated with clinically<br />symptomatic hypothyroidism.<br />The reduction in total and free T4 was maximal within the first six weeks of quetiapine treatment,<br />with no further reduction during long-term treatment. For about 2/3 of all cases, cessation of<br />quetiapine treatment was associated with a reversal of the effects on total and free T4,<br />irrespective of the duration of treatment.<br />Cataracts/lens opacities<br />In a clinical trial to evaluate the cataractogenic potential of Quetiapine (200-800 mg/day) versus<br />risperidone (2-8 mg/day) in patients with schizophrenia or schizoaffective disorder, the<br />percentage of patients with increased lens opacity grade was not higher in Quetiapine (4%)<br />compared with risperidone (10%), for patients with at least 21 months of exposure.</p><p>Paediatric population<br />Clinical efficacy<br />The efficacy and safety of Quetiapine was studied in a 3-week placebo controlled study for the<br />treatment of mania (n= 284 patients from the US, aged 10-17). About 45% of the patient<br />population had an additional diagnosis of ADHD. In addition, a 6-week placebo controlled study<br />for the treatment of schizophrenia (n = 222 patients, aged 13-17) was performed. In both studies,<br />patients with known lack of response to Quetiapine were excluded. Treatment with Quetiapine<br />was initiated at 50 mg/day and on day 2 increased to 100 mg/day; subsequently the dose was<br />titrated to a target dose (mania 400-600 mg/day; schizophrenia 400-800 mg/day) using<br />increments of 100 mg/day given two or three times daily.<br />In the mania study, the difference in LS mean change from baseline in YMRS total score (active<br />minus placebo) was &ndash;5.21 for Quetiapine 400 mg/day and &ndash;6.56 for Quetiapine 600 mg/day.<br />Responder rates (YMRS improvement &ge;50%) were 64% for Quetiapine 400 mg/day, 58% for<br />600 mg/day and 37% in the placebo arm.<br />In the schizophrenia study, the difference in LS mean change from baseline in PANSS total score<br />(active minus placebo) was &ndash;8.16 for Quetiapine 400 mg/day and &ndash;9.29 for Quetiapine 800<br />mg/day. Neither low dose (400 mg/day) nor high dose regimen (800 mg/day) quetiapine was<br />superior to placebo with respect to the percentage of patients achieving response, defined as<br />&ge;30% reduction from baseline in PANSS total score. Both in mania and schizophrenia higher<br />doses resulted in numerically lower response rates.<br />In a third short-term placebo-controlled monotherapy trial with Quetiapine in children and<br />adolescent patients (10-17 years of age) with bipolar depression, efficacy was not demonstrated.<br />No data are available on maintenance of effect or recurrence prevention in this age group.<br />Clinical safety<br />In the short-term pediatric trials with quetiapine described above, the rates of EPS in the active<br />arm vs. placebo were 12.9% vs. 5.3% in the schizophrenia trial, 3.6% vs. 1.1% in the bipolar<br />mania trial, and 1.1% vs. 0% in the bipolar depression trial. The rates of weight gain &ge; 7% of<br />baseline body weight in the active arm vs. placebo were 17% vs. 2.5% in the schizophrenia and<br />bipolar mania trials, and 13.7% vs. 6.8% in the bipolar depression trial. The rates of suicide related events in the active arm vs. placebo were 1.4% vs. 1.3% in the schizophrenia trial, 1.0%<br />vs. 0% in the bipolar mania trial, and 1.1% vs. 0% in the bipolar depression trial. During an<br />extended post treatment follow-up phase of the bipolar depression trial, there were two additional<br />suicide related events in two patients; one of these patients was on quetiapine at the time of the<br />event.<br />Long-term safety<br />A 26-week open-label extension to the acute trials (n=380 patients), with Quetiapine flexibly<br />dosed at 400- 800 mg/day, provided additional safety data. Increases in blood pressure were<br />reported in children and adolescents and increased appetite, extrapyramidal symptoms and<br />elevations in serum prolactin were reported with higher frequency in children and adolescents<br />than in adult patients (see Sections 4.4 and 4.8). With respect to weight gain, when adjusting for<br />normal growth over the longer term, an increase of at least 0.5 standard deviation from baseline<br />in Body Mass Index (BMI) was used as a measure of a clinically significant change; 18.3% of<br />patients who were treated with quetiapine for at least 26 weeks met this criterion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Quetiapine is well absorbed and extensively metabolised following oral administration. The<br />bioavailability of quetiapine is not significantly affected by administration with food. Steadystate<br />peak molar concentrations of the active metabolite norquetiapine are 35% of that observed<br />for quetiapine.<br />The pharmacokinetics of quetiapine and norquetiapine are linear across the approved dosing<br />range.<br />Distribution<br />Quetiapine is approximately 83% bound to plasma proteins.<br />Biotransformation<br />Quetiapine is extensively metabolised by the liver, with parent compound accounting for less<br />than 5% of unchanged drug-related material in the urine or faeces, following the administration<br />of radiolabelled quetiapine. In vitro investigations established that CYP3A4 is the primary enzyme responsible for cytochrome P450 mediated metabolism of quetiapine. Norquetiapine is<br />primarily formed and eliminated via CYP3A4.<br />Approximately 73% of the radioactivity is excreted in the urine and 21% in the faeces.<br />Quetiapine and several of its metabolites (including norquetiapine) were found to be weak<br />inhibitors of human cytochrome P450 1A2, 2C9, 2C19, 2D6 and 3A4 activities in vitro. In vitro<br />CYP inhibition is observed only at concentrations approximately 5 to 50 fold higher than those<br />observed at a dose range of 300 to 800 mg/day in humans. Based on these in vitro results, it is<br />unlikely that co-administration of quetiapine with other drugs will result in clinically significant<br />drug inhibition of cytochrome P450 mediated metabolism of the other drug. From animal studies<br />it appears that quetiapine can induce cytochrome P450 enzymes. In a specific interaction study in<br />psychotic patients, however, no increase in the cytochrome P450 activity was found after<br />administration of quetiapine.<br />Elimination<br />The elimination half lives of quetiapine and norquetiapine are approximately 7 and 12 hours,<br />respectively. The average molar dose fraction of free quetiapine and the active human plasma<br />metabolite norquetiapine is &lt;5% excreted in the urine.<br />Special populations<br />Gender<br />The kinetics of quetiapine do not differ between men and women.<br />Elderly<br />The mean clearance of quetiapine in the elderly is approximately 30 to 50% lower than that seen<br />in adults aged 18 to 65 years.<br />Renal Impairment<br />The mean plasma clearance of quetiapine was reduced by approximately 25% in subjects with<br />severe renal impairment (creatinine clearance less than 30 ml/min/1.73m2), but the individual<br />clearance values are within the range for normal subjects.<br />Hepatic Impairment<br />The mean quetiapine plasma clearance decreases with approx. 25% in persons with known<br />hepatic impairment (stable alcohol cirrhosis). As quetiapine is extensively metabolised by the liver, elevated plasma levels are expected in the population with hepatic impairment. Dose<br />adjustments may be necessary in these patients (see Section 4.2).<br />Paediatric population<br />Pharmacokinetic data were sampled in 9 children aged 10-12 years old and 12 adolescents, who<br />were on steady-state treatment with 400 mg quetiapine twice daily. At steady-state, the dosenormalised<br />plasma levels of the parent compound, quetiapine, in children and adolescents (10-17<br />years of age) were in general similar to adults, though Cmax in children was at the higher end of<br />the range observed in adults. The AUC and Cmax for the active metabolite, norquetiapine, were<br />higher, approximately 62% and 49% in children (10-12 years), respectively and 28% and 14% in<br />adolescents (13-17 years), respectively, compared to adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There was no evidence of genotoxicity in a series of in vitro and in vivo genotoxicity studies. In<br />laboratory animals at a clinically relevant exposure level the following deviations were seen,<br />which as yet have not been confirmed in long-term clinical research:<br />In rats, pigment deposition in the thyroid gland has been observed; in cynomolgus monkeys<br />thyroid follicular cell hypertrophy, a lowering in plasma T3 levels, decreased haemoglobin<br />concentration and a decrease of red and white blood cell count have been observed; and in dogs<br />lens opacity and cataracts. (For cataracts/lens opacities, see Section 5.1).<br />In an embryofetal toxicity study in rabbits the foetal incidence of carpal/tarsal flexure was<br />increased. This effect occurred in the presence of overt maternal effects such as reduced body<br />weight gain. These effects were apparent at maternal exposure levels similar or slightly above<br />those in humans at the maximal therapeutic dose. The relevance of this finding for humans is<br />unknown.<br />In a fertility study in rats, marginal reduction in male fertility and pseudopregnancy, protracted<br />periods of diestrus, increased precoital interval and reduced pregnancy rate were seen. These<br />effects are related to elevated prolactin levels and not directly relevant to humans because of<br />species differences in hormonal control of reproduction</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core:<br /> Lactose Monohydrate<br /> Microcrystalline Cellulose PH 101<br /> Dibasic Calcium Phosphate Dihydrate<br /> Sodium Starch Glycollate<br /> Povidone K 90<br /> Microcrystalline Cellulose PH 102<br /> Colloidal Silicone Dioxide (Aerosil 200)<br /> Magnesium Stearate<br /> Purified Water<br />Coating:<br /> Opadry White 03B28796 (which consist of (which consists of Hypromellose, Titanium<br />dioxide, Polyethylene Glycol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (24 Months).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sequit (Quetiapine) 25/100/200/300 mg Film Coated is packed in Aluminium foil and Opaque<br />PVC /PVDC, blister pack of 3x10&rsquo;s.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>